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Abstract 
Vitamin B12 is a water-soluble nutrient that is the largest and most structurally 
complex of all the known vitamins, requiring over thirty enzymatic steps for its 
biosynthesis. The work carried out here investigates the possibility of engineering 
the production of B12 variants, through the construction of an empty, metal-free B12 
shell, and exploring what effect such compounds might have on cellular control 
elements, such as riboswitches. In order to study this, a method was designed and 
developed that utilises an ‘in vitro’ system to determine the effect of B12 variants on 
a well-characterised B12-dependent riboswitch known as the btuB riboswitch. This 
method allows a quick and easy way of testing the ability of B12 variants to directly 
bind to and deactivate the btuB riboswitch, without relying on indirect cellular 
effects. 
 
The production of such a technique required the construction of a plasmid in which 
the btuB riboswitch was placed upstream of the eGFP reporter gene. This plasmid 
was combined with in vitro transcription/translation machinery, in the presence of 
different B12 variants, of both natural and unnatural origin, to see how each affects 
the levels of eGFP production. eGFP production was monitored in the presence of 
AdoCbl, AdoRbl, CNCbl, AdoCbi, CNCbi, Nibl, Znbl, EtPhCbl and F2PhEtyCbl. The 
results showed that AdoCbl and AdoRbl had the greatest effect on the riboswitch, 
with AdoRbl closely mimicking the levels of inhibition caused by AdoCbl. CNCbl, 
AdoCbi and CNCbi were seen to have much lesser effects and required higher 
concentrations to cause similar effects to that of AdoCbl or AdoRbl. The remaining 
four B12 variants were seen to have little effect, if any. Overall, results showed that 
an adenosyl group in place of the upper ligand is crucial to riboswitch recognition.  
The demonstration that AdoRbl is able to bind to the riboswitch highlights the 
potential for such analogues, with the required components for recognition, to 
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interfere with and inhibit cellular processes. Thus, the research carried out here 
opens up an exciting new field of research into the use of B12 analogues as 
antibacterial agents.   
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Chapter 1: Introduction 
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1.1 What is B12 
1.1.1 B12 Overview 
Vitamin B12 is a water-soluble vitamin that is the largest and most structurally 
complex of all the known vitamins. It is unique among the vitamins due to the fact 
that it is synthesised only by prokaryotes (Roth et al 1996; Warren et al, 2002). It 
was first identified as the anti-pernicious anaemia factor found in crude liver extract 
through the work of George Whipple, George Minot and William Murphy (Minot and 
Murphy, 1926; Whipple et al 1920) . Following this, the chemical structure was 
elucidated in 1955 by Dorothy Hodgkin and her team (Hodgkin et al, 1955) which 
was the largest crystal structure to be determined by crystallographic analysis at 
that time. It is now known to have a role in normal brain functioning (Weir and Scott, 
1999) and the formation of red blood cells (Koury and Ponka, 2004). Technically, 
vitamin B12 is a specific form of cobalamin called cyanocobalamin. However, the 
term B12 will be used here to refer to cobalamin in general, largely to cover the more 
common versions of the molecule, adenosylcobalamin (AdoCbl), methylcobalamin 
(MeCbl) and cyanocobalamin (CNCbl). 
 
1.1.2 Structure of B12 
B12 contains a modified tetrapyrrole that houses a cobalt ion at its centre (Figure 
1.1), which is referred to as a corrin ring. The corrin ring is the core component of 
the vitamin with various attached side groups, including upper and lower axial 
ligands, the latter of which is connected to the corrin ring via the nucleotide loop 
(Figure 1.1) (Roth et al, 1996). The cobalt ion is able to form six bonds, four of 
which it forms with nitrogen atoms (from the four pyrrole subunits, named A-D, 
which are coordinated in plane to the central cobalt ion) and the remaining two with 
the upper and lower ligands found in the structure of B12 (Figure 1.1). The upper 
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ligand is generally variable, while the lower ligand of cobalamin is 5,6-
dimethylbenzimidazole (DMB), which is attached to the periphery of the corrin ring 
(ring D) via an aminopropanol linker. The presence of DMB at the lower ligand 
position defines the molecule as cobalamin. When any other base is present, the 






































Figure 1.1. General structure of B12 (cobalamin). (DMB at the lower ligand 
position shown inside red circle). X = upper ligand, M = central metal ion. The 


























In addition to the variation created by the nature of the upper ligand, greater 
structural complexity arises from the ability of B12 to have two different 
conformations known as “base on” or “base off”. Determination of which of the two 
conformations the molecule is in depends on the presence of a bond between the 
cobalt ion and DMB, represented by the dotted line in Figure 1.1, which when 
present, represents the “base on” conformation (Mathews et al, 2007). In certain 
forms of B12, this bond is broken and the molecule is said to be in the “base off” 
conformation. This broken bond is often a result of B12 binding to certain proteins, 
where conformational changes cause bond breakage (Wuerges et al, 2006).  
 
1.1.3 Upper and lower ligands of B12 
Due to the variable nature of the upper ligand, there are a number of different forms 
of B12. Most common forms include AdoCbl, MeCbl, and CNCbl with upper ligands 
of 5’deoxyadenosyl-, methyl-, or cyano-, respectively. Of these, AdoCbl and MeCbl 
are the biologically active forms in humans (Marsh, 1999), whose roles are 
discussed in Section 1.3. 
 
Use of cobamides (cobalt-containing corrins with upper and lower ligands, of which 
cobalamin is an example) is far more widespread across the bacterial kingdom than 
its biosynthesis (Shelton et al, 2018). This suggests that the majority of cobamide-
requiring bacteria take up incomplete corrinoids from their environment and 
synthesise lower ligands for completion of these molecules. Different bacteria use 
different lower ligands depending on their enzyme specificity as well as on the 
molecules or lower ligand forming components present in their environment (Crofts 
et al, 2013; Hazra et al, 2013). For example, Lactobacillus reuteri is a bacterium 
which assigns adenine at the lower ligand position, instead of DMB, in order to form 
pseudocobalamin (Santos et al, 2007).  Research has shown that most bacteria 
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have enzymes that preferentially attach DMB as the lower ligand of B12, but are 
capable of using a wide range of lower ligand substrates (Hazra et al, 2013). The 
lower ligand bases of cobamides can be divided into one of three chemical classes: 
benzimidazoles, purines and phenolics (Figure 1.2) (Hazra et al, 2013; Shelton et 
al, 2018). 




Different B12-dependent enzymes require different forms of cobamides. This can be 
dependent upon either the presence of a certain type of upper ligand, a certain type 
of lower ligand or even dependent upon whether the molecule is in “base-on” or 
“base-off” conformation. For example, for enzymes such as class II ribonucleotide 
reductases, the cobamide has been shown to bind the enzyme in the “base-on” 
form (Abend et al., 1999; Lawrence et al., 1999). Meanwhile, enzymes such as 
methionine synthase and methylmalonyl CoA mutase require cobalamin to bind in 
the “base-off” conformation (Drennan et al 1994; Mancia et al, 1996). However, with 
both “base-on” and “base-off” requiring enzymes, it is thought that the structure of 
the lower ligand may also affect the binding of the cobamide (Hamza et al, 2005; 
















Figure 1.2. Lower ligand structure classes. Benzimidazoles: R1, R2 = H, OH, 
CH3, OCH3. Purines: R1= H, CH3, NH2; R2 = H, NH2, OH, O. Phenolics: R = H, 
CH3 Imaged adapted from (Shelton et al, 2018)  
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production only to the forms required by the enzymes they contain (Chan and 
Semerena, 2011; Hazra et al, 2013).  
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1.2 B12 Biosynthesis 
1.2.1 Biosynthesis Overview 
Vitamin B12 is unique among the vitamins in that it is made solely by only certain 
bacteria and archaea. De novo synthesis of B12 is a highly complex process that 
requires ~30 enzymes (Warren et al, 2002). There are two genetically distinct 
pathways for B12 biosynthesis, one being the aerobic pathway, which is utilised by 
bacteria such as Pseudomonas denitrificans (Blanche et al 1995) and the other 
being the anaerobic pathway, which is employed by bacteria such as Bacillus 
megaterium (Moore and Warren, 2012). The aerobic B12 biosynthesis pathway is 
different to the anaerobic pathway in that it requires not only the presence of 
molecular oxygen, but also late cobalt insertion in the pathway (Heldt et al, 2005; 
Warren et al, 2002).  
 
In both cases, B12 is derived from uroporphyrinogen III (uro’gen III) (Warren and 
Scott, 1990). Of the two biosynthesis pathways, the aerobic pathway has more 
stable intermediates and is therefore, more commonly studied. Similarly, the work 
involved in this report will also largely be based around the aerobic B12 biosynthesis 
pathway (Figure 1.3 and 1.4). 
 
1.2.2 Aerobic Biosynthesis Pathway 
The first enzyme involved in the aerobic biosynthesis of AdoCbl is CobA, which 
methylates the starting material, uro’gen III, at C2 and C7 in order to generate 
precorrin-2. This is followed by CobI which methylates precorrin-2 at C20, such that 
it is converted into precorrin-3A. The next enzyme in the pathway is CobG which 
catalyses hydroxylation of precorrin-3A at C20, resulting in the formation of 
precorrin-3B. Precorrin-3B is methylated by CobJ, at C17, following which the 
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crucial ring contraction step occurs and leads to the formation of precorrin-4 
(Warren et al, 2002).  
 
CobM is the subsequent enzyme in line, which methylates precorrin-4 at C11 to 
form precorrin-5, followed by CobF which methylates precorrin-5 at C1, to generate 
precorrin-6A. Next, CobK converts precorrin-6A to precorrin-6B, via C18-19 
reduction, which is then acted upon by CobL, an enzyme catalysing C5 and C15 
methylation as well as decarboxylation of the acetate group at C12, to generate 
precorrin-8. C11-C12 of precorrin-8 is subject to methyl rearrangement, by the 
action of CobH, in order to form hydrogenobyrinic acid, HBA. HBA is amidated by 
CobB, resulting in the formation of HBA-diamide (HBAD) (Warren et al, 2002).  
 
Cobalt insertion is a major and crucial step in B12 biosynthesis. B12 rarely exists 
without the cobalt ion, except in certain photosynthetic bacteria, such as, 
Allochromatium vinosum, from which corrinoid compounds have been found 
containing no cobalt (Toohey, 1965), most likely a consequence of growing the 
organism in the absence of cobalt. 
 
In the majority of bacteria, however, three proteins are involved in cobalt insertion; 
CobN, CobS and CobT, which convert HBAD into cob(II)yrinic acid a,c-diamide, 
before reduction of cobalt by CobR to form cob(I)yrinic acid a,c-diamide (Warren et 
al, 2002). The next step is the adenosylation of cob(I)yrinic acid a,c-diamide, by 
CobO, to give adenosylcobyrinic acid a,c-diamide. This is then subject to b, d, e, g- 
amidation by CobQ to give adenosylcobyric acid (Warren et al, 2002).  
 
The final stage of B12 biosynthesis involves the synthesis and assembly of the lower 
nucleotide loop. As mentioned previously, the lower loop is attached to the corrin 
ring via an aminopropanol linker. The synthesis of this aminopropanol linker begins 
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with the actions of the CobC enzyme (referred to as CobD in the anaerobic 
pathway, for example in bacteria such as Salmonella enterica). CobC, a small 
dimeric enzyme known as L-threonine phosphate decarboxylase, catalyses the 
synthesis of aminopropanol phosphate from L-threonine phosphate, which is the 
crucial component that links the lower nucleotide loop to the corrin ring, at C17 of 
ring D (Cheong et al, 2002). L-threonine phosphate, itself, is synthesised from 
threonine by the action of a kinase called PduX (Fan and Bobik, 2008). In the 
aerobic pathway, CobC is thought to be part of a complex called ‘protein b’ with the 
cobinamide synthase, CobD (known as CbiB in the anaerobic pathway). Protein b 
(CobC and CobD complex) is thought to work together with another protein, protein 
a, to catalyse attachment of aminopropanol to adenosylcobyric acid in the presence 
of ATP and Mg2+ (Blanche et al, 1995), however, the exact function, identity and 
role of protein a is unknown. Together, CobC and CobD facilitate aminopropanol 
synthesis and its attachment at C17 of adenosylcobyric acid, in order to generate 
adenosylcobinamide (AdoCbi) (Warren et al, 2002). 
 
Next, the bifunctional enzyme, CobP (known as CobU in the anaerobic biosynthesis 
pathway), initiates the process of assembling the lower loop by converting AdoCbi 
into AdoCbi-GDP (Warren et al, 2002). CobP is a small homodimeric protein with 
two different enzymatic functions, one as cobinamide kinase and the other as 
cobinamide phosphate guanylyltransferase. In the first step, CobP catalyses 
phosphorylation of the hydroxyl group of the aminopropanol in AdoCbi, using an 
ATP donor molecule, to form AdoCbi-phosphate (AdoCbi-P). In the second step, 
CobP transfers a GMP moiety, from a GTP donor, onto the phosphate group to form 
AdoCbi-GDP (Blanche et al, 1991).  
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Finally, lower ligand synthesis and assembly require two enzymes, nicotinate-
nucleotide-dimethylbenzimidazole phosphoribosyltransferase, which is more 
commonly known as CobU (CobT in the anaerobic pathway) and cobalamin 
synthase, more commonly known as CobV (CobS in the anaerobic pathway) to form 
AdoCbl from AdoCbi-GDP (Warren et al, 2002). To begin with, CobU synthesises a-
linked riboside monophosphates from a diverse range of nucleotide base substrates 
(generally one of benzimidazoles, purines or phenolics, as mentioned in Section 
1.1.3) (Chan et al, 2014), for which reason there is such diversity in the possible 
lower ligands found within cobamides (Shelton et al, 2018). Generally, however, the 
preferred ligand which is attached and activated by the enzyme is DMB (Figure 1.1) 
(Hazra et al, 2013; Shelton et al, 2018). This activation involves the formation of a 
glycosidic bond between the ribose of b-nicotinate mononucleotide (NaMN) and 
DMB, in order to form α-ribazole phosphate (Blanche et al, 1991; Mander and Liu, 
2010; Trzebiatowski et al, 1994). DMB, unless obtained from the environment, is 
synthesised from FMNH2 by an enzyme called BluB (an oxidoreductase found in the 
aerobic biosynthesis pathway) (Mander and Liu, 2010). More recently, it has been 
found that DMB can also be synthesised anaerobically (Hazra et al, 2015). 
Following this synthesis of the lower loop (α-ribazole phosphate) is its assembly to 
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Figure 1.4. The conversion of adenosyl-cob(III)yric acid to 
adenosylcob(III)alamin 
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1.2.3 Allochromatium vinosum 
Currently in this field very little is known about metal-free corrinoids in relation to 
both their structure and behaviour, in comparison to natural corrinoids. In 1965, 
metal-free corrinoids were first discovered and isolated from the photosynthetic 
bacterium, A. vinosum (Toohey, 1965). Four of these metal-free corrinoids were 
investigated for potential activity as B12 inhibitors, whereby growth inhibition was 
seen in E. coli (Perlman and Toohey, 1966). Following on from this, a whole new 
class of metal-substituted B12 analogues were synthesised using metal-free 
corrinoids isolated from A. vinosum (Koppenhagen and Piffner,1970).  
 
One of the aims of this project involves the synthesis of hydrogenobalamin (a metal-
free B12 shell) using enzymes from A. vinosum, to be used as the starting material 
for creating unnatural B12 analogues that act as B12 antagonists or inhibitors.  
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1.3 Role of B12  
1.3.1 Overview of the function of B12 
There are four main classes of B12-dependent enzymes; the AdoCbl-dependent 
isomerases, the MeCbl-dependent methyltransferases, the radical SAM superfamily 
of B12-dependent enzymes and the less well studied reductive dehalogenases 
(Banerjee and Ragsdale, 2003). It is the C-Co bond in B12 that gives the molecule 
its reactivity and is utilised by B12-dependent enzymes. However, the bond is 
exploited differently depending on which enzyme is using the molecule, for 
example, the isomerases rupture the bond homolytically, while the 
methyltransferases cleave the bond heterolytically (Banerjee and Ragsdale, 2003). 
 
1.3.2 Role in eukaryotes 
B12 plays a key role in a number of essential biological processes. In humans, for 
example, there are two B12-dependent enzymes, methionine synthase and 
methylmalonyl-CoA mutase (Banerjee et al, 2009).  
 
MeCbl is a cofactor for methionine synthase, a methyltransferase which 
regenerates methionine from homocysteine (Brown, 2005; Stubbe, 1994). AdoCbl, 
on the other hand, is a coenzyme for methylmalonyl-CoA mutase, an isomerase 
which converts methylmalonyl-CoA to succinyl-CoA (Andrès et al, 2004; Brown, 
2005; Clardy et al, 2011; Marsh, 1999). Without the actions of these two B12-
dependent enzymes (Figure 1.5) there would be abnormal functioning of the brain 
and nervous system, due to their requirement for nucleic acid synthesis and the 
methylation reactions of the brain (Weir and Scott, 1999). A lack of MeCbl leads to a 
build-up of homocysteine and therefore S-adenosylhomocysteine (SAH), which 
inhibits SAM-mediated methylation reactions. SAM (synthesised from methionine by 
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the actions of the enzyme, S-adenosylmethionine synthetase) is required for 
maintaining methylation reactions, since it is used by many methyltransferases as a 
methyl group donor. Inhibition of these methylation reactions is thought to cause 
cobalamin deficiency associated neuropathy. It is this maintenance of methylation 
reactions by SAM that is the main function of B12 in the brain and liver, as well as in 
rapidly dividing cells, such as the bone marrow, where DNA synthesis is hindered 
due to a lack of B12 (Weir and Scott, 1999). Since blood cells are generated in the 
bone marrow, an inhibition of DNA synthesis in bone marrow cells will prevent their 



















Figure 1.5. The reactions catalysed by the two B12 dependent enzymes found 
in humans, methionine synthase and methylmalonyl-CoA mutase. Methionine 
synthase catalyses the transfer of a methyl group from methyltetrahydrofolate 
(CH3-H4-folate) to homocysteine to form methionine. Methylmalonyl-CoA mutase 
catalyses the isomerisation of methylmalonyl-CoA to form succinyl-CoA. 
Methionine Synthase 
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Caenorhabditis elegans is a simple model organism, which has been demonstrated 
to be a useful tool for the study of B12 uptake in eukaryotic organisms (Bito et al, 
2013). C. elegans, a nematode worm, has been found to contain the same two B12-
dependent enzymes as in humans and requires B12 for sufficient growth. A B12-
deficiency in worms can cause infertility, shorter lifespans and delayed growth (Bito 
and Watanabe, 2016). In more recent studies, through the use of fluorescent corrin 
analogues, it has been shown that the organism only takes up the complete 
cobalamin molecule and not incomplete corrinoids (Lawrence et al, 2018). 
 
Plants are another interesting area of study in the field of B12 research, since a 
major cause of B12-deficiency in humans is the plant-based diet consumed by 
vegetarians and vegans (Stabler and Allen, 2004) . In plants, there currently 
appears to be no known role of B12 and therefore no known import system 
developed for the molecule. However, certain photosynthetic organisms, such as 
microalgae, have been found to take up small amounts of the vitamin (Croft et al, 
2005). 
 
1.3.3 Role in prokaryotes 
As well as in humans, B12 is a molecule that is required by a significant proportion of 
the bacterial world due to the presence of B12-dependent enzymes in their cells 
(Shelton et al, 2018). One common subfamily of B12-dependent enzymes in bacteria 
are the isomerases, which are generally found only in bacteria, except for 
methylmalonyl-CoA mutase which is found in both bacteria and humans (Banerjee 
and Ragsdale, 2003). These include the AdoCbl-dependent ribonucleotide 
reductases (RNRs), which catalyse the conversion of ribonucleotides to 
deoxyribonucleotides, a step which is essential for DNA replication and repair 
(Banerjee, 1999; Nordlund and Eklund, 1993), glutamate mutase, which is able to 
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convert glutamate into methylaspartate and vice versa (Reitzer et al, 1999), and 
methylmalonyl-CoA mutase which catalyses the isomerisation of methylmalonyl-
CoA to form succinyl-CoA, (Figure 1.5). Other isomerases in this subfamily include 
methyleneglutarate mutase, isobutryl-CoA mutase and lysine 5,6 aminomutase 
(Banerjee and Ragsdale, 2003) . 
 
Another major class of B12-dependent enzymes in prokaryotes are the B12-
dependent methyltransferases, which catalyse the movement of a methyl group 
from a methyl donor to a methyl acceptor (Banerjee & Ragsdale, 2003). The most 
extensively studied enzyme of this class is the B12-dependent version of methionine 
synthase, MetH, which, as mentioned previously, regenerates methionine from 
homocysteine (Figure 1.5). Other corrinoid-dependent methyltransferases include 
acyl-CoA synthases and coenzyme M methyltransferases (Matthews et al, 2008). 
 
The radical SAM superfamily of enzymes is a major family of enzymes, of which the 
B12-dependent enzymes is the largest class (Bridwell-Rabb et al, 2014). The radical 
SAM family B12-dependent enzymes catalyse methyl transfer, using MeCbl as their 
methyl source (Frey et al, 2008). An example of one of these enzymes is BcpD, 
which is involved in the biosynthesis pathway of the herbicide, bialaphos (Frey et al, 
2008).  
 
The next well-known class of B12-dependent enzymes includes the reductive 
dehalogenases, which are involved in the detoxification of aromatic and aliphatic 
chlorinated organics, including chlorinated phenols, chlorinated ethane and 
polychlorinated biphenyls (Copley, 1998; Janssen et al, 2001). Bacterial exposure 
to these chlorinated compounds results in the expression of genes encoding 
reductive dehalogenases, such that they can remove the chloride ion from the 
compounds, thus playing an important role in detoxification (Banerjee and 
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Ragsdale, 2003). This class of enzymes is surprisingly unique in that these 
enzymes use a form of Cbl that lacks an upper ligand.  Recent advances have now 
shown another group of enzymes, known as the epoxyqueuosine reducatases 
(QueGs), also belong in this class along with the reductive dehalogenases. QueGs 
catalyse the reduction of epoxyqueuosine to form queuosine, an RNA nucleoside 
(Bridwell-Rabb & Drennan, 2017). 
 
Other recent advances have revealed a completely new role of B12 as a light sensor. 
For example, within the bacterial genome of Myxococcus xanthus genes are 
contained which encode carotenoids, pigments that are able to protect the cells 
from photooxidative damage. Research has shown that the expression of these 
genes is down-regulated by a transcriptional repressor, CarH, whose activity is 
specifically directed by the light sensitive B12 molecule, AdoCbl. It is during dark 
conditions when AdoCbl binds to the B12-binding motif found on CarH and forms a 
tetramer which interacts with the DNA and represses transcription. Upon light 
exposure, however, the C-Co bond of AdoCbl gets cleaved, causing the tetramer to 
fall apart, thereby allowing gene expression to occur (Jost et al, 2015; Ortiz-
Guerrero et al, 2011). This demonstrates how the light-sensing ability of AdoCbl 
allows it to play an indirect role in the regulation of gene expression, via its actions 
upon a transcription factor. 
 
In addition to playing a part in enzyme-catalysed reactions and having a role in light-
sensing, B12 has also been found to be involved in more direct gene regulation, in 
many bacteria, via short regions of RNA known as riboswitches (Rodionov et al, 
2003). More detail on riboswitches is given later in the chapter. A summary of the 
different B12-dependent processes, and the versions of B12 they require to carry out 
their function, is seen in Table 1.1. 
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Table 1.1. Table to show the versions of B12 required by each B12-dependent 
process. 
B12-dependent Process Required Version of B12 
Isomerisation AdoCbl 
Methylation MeCbl 
Radical SAM reaction MeCbl (sometimes AdoCbl) 
Reductive dehalogenation OHCbl 
Light responsive transcription regulation AdoCbl 




1.4 Uptake and transport of B12  
1.4.1 Uptake in eukaryotes 
In humans, B12 is crucial to life but cannot be synthesised de novo, for which reason 
several B12-binding proteins are involved in the process of B12 uptake from 
consumed food and its transport to the appropriate storage site. The first B12-binding 
protein involved, known as haptocorrin (also referred to as R-protein, cobalophilin 
and transcobalamin I), is found in the saliva and binds B12 straight after it has been 
ingested in order to protect it from the acidic environment of the stomach (Braun, 
2006; Lawrence and Roth, 1996). Despite its sensitivity to acid, the binding of B12 to 
haptocorrin allows the complex to pass through the stomach and into the small 
intestine. Pancreatic enzymes then digest haptocorrin, so that the released B12 
molecule can bind the second B12-binding protein known as intrinsic factor (IF). IF-
B12 complex is absorbed by the epithelial cells of the ileum, following which B12 is 
dissociated once again so that it can bind to the third B12-binding protein, 
transcobalamin II (TCN2) (Braun and Endriss, 2007) . Finally, the TCN2-B12 
complex exits the epithelial cells and is transported to the liver (Postle and Larsen, 
2007). 
 
As mentioned previously, nematode worms are another eukaryotic organism that 
require B12 for growth and also for the B12-dependent enzymes, methionine 
synthase and methylmalonyl-CoA mutase (Bito & Watanabe, 2016). They are 
unable to synthesise the molecule themselves and obtain B12 from the bacteria that 
they digest. However, the method of transport within C. elegans is currently not 
known. When a B12-deficiency is induced in the organism, symptoms resemble 
those seen in mammalian B12-deficiency, including infertility, delayed growth and a 
shorter lifespan (Bito & Watanabe, 2016). This makes nematode worms an 
organism of great interest in the study of B12-deficiency in eukaryotic organisms. 
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In terms of plants, there is no known requirement for B12 and therefore no 
designated uptake system. Algae, on the other hand, have been shown by recent 
research to contain a protein that is implicated in B12 uptake, CBA1. However, its 
role and mechanism of action remain unknown (Helliwell et al, 2016). It is thought 
that half of all algae require B12 and likely get it by having a symbiotic relationship 
with B12-producing bacteria (Croft et al, 2005). It has been known for years that 
bacteria are able to provide B12 to other bacteria or algae in mixed consortia. 
However, it is not known how bacteria transport B12 out of their cells. Since there is 
currently no known export system for B12 from bacterial cells, research into this area 
could lead the way towards finding one. 
 
1.4.2 Uptake in prokaryotes 
Around 86% of bacteria are thought to have at least one enzyme belonging to a B12-
dependent family of enzymes, yet only 37% are predicted to synthesize B12 de novo 
(Shelton et al, 2018). Those that are able to synthesize their own B12, such as 
Bacillus megaterium (Moore & Warren, 2012), do not rely on uptake of the vitamin. 
However, since the molecule is energetically very expensive to synthesise, bacteria 
will acquire it from their environment when possible.  Those that do not have this 
ability to synthesize B12 de novo rely on taking up the vitamin from their 
surroundings. 
 
Bacteria such as E. coli are unable to make their own B12, and therefore rely on the 
uptake of B12 from an external source using a tightly-regulated import system 
(Lewinson et al, 2010). Bacteria have evolved a number of B12 import systems over 
time, but currently the best characterized one is the BtuB import system in E. coli.  
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B12 uptake in E. coli relies on a large complex known as the TonB complex, 
consisting of three proteins (TonB, ExbD and ExbB) which span the periplasm and 
provide the proton motive force (from the cytoplasmic membrane) required to take 
up B12 via the TonB-dependent transporter (TBDT), an outer membrane transporter 
known as BtuB (Johnson Jr et al, 2012; Lundrigan et al, 1991; Nahvi et al, 2002). 
B12 is a complex molecule that needs to be actively transported across the 
membrane with the help of transporter proteins. BtuB is the first of these proteins 
which imports B12 from outside the cell, using energy provided by the TonB 
complex, and transports it to the periplasm (Cadieux et al., 2002). Once in the 
periplasm, the periplasmic protein BtuF binds B12 tightly and delivers it to the 


























Figure 1.6. Diagram representing the B12 import system in E. coli. B12 is 
transported into the periplasm by the outer membrane transporter, BtuB, which is 
powered by the TonB complex (TonB, ExbB and ExbD). It is then bound by the 
periplasmic protein, BtuF, which transports it to the BtuC/D complex. The BtuC/D 
complex allows its import into the cytoplasm. 
B12 
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BtuC is a transmembrane protein and BtuD is an ATP Binding Cassette (ABC) 
transporter (Cadieux et al, 2002), and together they form the BtuC/D complex. 
BtuC/D cannot bind free B12 very well on its own, unlike BtuF which has a very high 
affinity for the molecule, and therefore requires BtuF to deliver B12 directly to its 
complex. Once the BtuF-B12 complex reaches BtuC/D, both complexes associate 
and undergo a conformational change whereby the BtuC/D complex causes BtuF to 
release B12 and allows its internalisation into the cytoplasm through BtuC/D. In the 
final stage, energy from ATP is required to release BtuF from the complex and this 
is provided when the ATP bound to BtuD is hydrolysed (Lewinson et al, 2010). BtuF 
is then free to re-initiate the cycle of B12 delivery. 
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1.5 B12 Riboswitch 
1.5.1 Riboswitch overview 
Riboswitches are highly structured regulatory elements, found within mRNA 
sequences, that are bound to by a ligand or metabolite to terminate transcription or 
translation (Breaker, 2012; Serganov and Nudler, 2013). One of the first discovered 
riboswitch types was the B12 riboswitch, where binding of B12 results in the switching 
off of expression of B12-related genes. Following this, many other riboswitches, 
including the thiamine pyrophosphate (TPP) and S-adenosylmethionine (SAM) 
riboswitches, were also identified and studied.  
 
There are three common mechanisms utilised by riboswitches to prevent 
expression of the downstream gene(s), which include transcription termination, 
prevention of translation initiation or splicing (in eukaryotes) (Breaker, 2012) (Figure 
1.7).  
 
In the first mechanism, the formation of a strong terminator stem followed by a run 
of uridine residues results in the generation of an intrinsic transcription terminator 
(Gusarov and Nudler, 1999; Yarnell and Roberts, 1999). The formation of this 
terminator stem is controlled by ligand binding to the riboswitch, which causes RNA 
polymerase to stall transcription and release any associated substrates or products 
(Breaker, 2012) (Figure 1.7A). Similarly, riboswitches that control translation 
initiation also work through a change in mRNA structure, where the formation of a 
hairpin structure, that sequesters the ribosome-binding site (RBS), prevents binding 
of the ribosome and therefore significantly reduces the likelihood of translation 
initiation (Nou and Kadner, 1998) (Figure 1.7B). Finally, another class of 
riboswitches found in eukaryotes, including some of those controlled by TPP, have 
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been shown to control gene expression through splicing (Cheah et al, 2007; 





Figure 1.7. Diagram representing the three common mechanisms utilised 
by riboswitches to prevent expression of downstream gene(s). A) 
Transcription termination, B) termination of translation initiation, C) gene splicing 
(eukaryotes). Image adapted from Breaker, 2012. 
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1.5.2 B12-dependent riboswitches 
The btuB riboswitch is one of a number of different B12-dependent riboswitches. 
Other examples of B12 binding riboswitches include the metE riboswitch, which 
controls production of a B12-independent methionine synthase (encoded by metE) 
(Warner et al, 2007), and the Pacific Ocean metagenome env8 riboswitch controlled 
by the less common ligand, OHCbl (Johnson Jr et al, 2012).  
 
The metE riboswitch is controlled by AdoCbl, which binds to a ‘B12 element’ on the 
riboswitch to switch it off via regulation at the transcriptional level (Rodionov et al, 
2003). This results in a decrease in the levels of B12-independent methionine 
synthase (MetE) found within cells. This is of particular importance when levels of 
AdoCbl are high in the cell, as it has been shown that the B12-dependent version 
(MetH) is over 100 times more active than MetE and therefore, there is a metabolic 
advantage of using MetH instead of MetE when possible (i.e. when levels of B12 
inside the cell are high) (Gonzalez et al, 1992; Jeter et al, 1984). 
 
Currently, two B12 riboswitches have had their structures solved using X-ray 
crystallisation techniques, one from Symbiobacterium thermophilum (Peselis and 
Serganov, 2012) and another from Thermoanaerobacter tengcongensis (Tte) 
(Johnson Jr et al, 2012) (Figure 1.8). The AdoCbl riboswitch has a unique structure, 
allowing for AdoCbl to bind (Figure 1.8). The AdoCbl riboswitch has three main 
regions; the peripheral region which is thought to be involved in ligand recognition, 
the core region which contains the ligand binding site, and the accessory region 
(often referred to as the expression platform), which changes structure in response 
to ligand binding at the core region. Comparative sequence analysis studies 
suggest that the core region, containing the AdoCbl binding site, is highly conserved 
through evolution (Peselis and Serganov, 2012).
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Figure 1.8. S. thermophilum AdoCbl riboswitch structure. (a) Consensus 
secondary structure of the AdoCbl riboswitch. Red nucleotides are conserved in 
more than 90% of species. (b) Schematic of the riboswitch fold observed in the 
crystal structure of the complex. Key long-distance tertiary base-pairing and 
stacking interactions are shown as dashed lines. (c, d) Ribbon representation of 
overall AdoCbl riboswitch structure. Adapted from: (Peselis and Serganov, 2012)  
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1.5.3 E. coli btuB riboswitch  
Initial work on the E. coli btuB riboswitch was initiated when levels of btuB 
expression within E. coli cells were found to be controlled by an mRNA leader 
sequence starting 240 nucleotides upstream of the start of translation. In addition to 
this, btuB sequences between +156 and +365 were also seen to strongly influence 
gene expression in response to B12 levels (Lundrigan et al, 1991). At the same time, 
Lundrigan et al showed that despite the role of BtuB in uptake of B12 into cells, it 
does not appear to be directly involved in its own regulation. Within the mRNA 
leader sequence of the btuB gene lies the B12 box (Figure 1.9) which is the region to 
which B12 is thought to bind (Franklund and Kadner, 1997) and, in particular, with 
AdoCbl as the preferred ligand (Lundrigan and Kadner, 1989).  
 
Regulation by B12 operates at both the transcriptional and translational level, with 
both types suggested to have inhibitory elements that act independently (Franklund 
and Kadner, 1997). However, primary control over btuB expression was found to be 
at the level of translation initiation, where the formation of a hairpin structure 
sequesters the RBS such that the ribosome can no longer bind (Nou and Kadner, 
1998). 
 
The mRNA leader sequence, in the 5’ untranslated region (UTR) of the btuB gene, 
was later discovered to be an AdoCbl-responsive riboswitch. This btuB riboswitch 
controls btuB gene expression in response to AdoCbl binding. AdoCbl was found to 
bind directly to the mRNA and induce a structural reorganisation, which results in a 
change in expression levels (Nahvi et al, 2002).  
 
The btuB riboswitch is thought to have two main domains; the aptamer domain 
(containing the peripheral region and core region, as mentioned above) and the 
 48 
expression platform (Gruber et al, 2011) (Figure 1.9). The aptamer domain is highly 
conserved amongst various organisms and it is within the core region that the B12 
box is located (Nahvi et al, 2004). Once AdoCbl binds at the B12-box, the riboswitch 
structure is thought to change at the expression platform such that the RBS gets 
sequestered and is no longer accessible by the ribosome (Gruber et al, 2011) thus 





Figure 1.9. E. coli btuB riboswitch proposed model. Adapted from: (Gruber et 
al. 2011). The btuB riboswitch regulates translation of BtuB by AdoCbl-binding. At 
high AdoCbl (coenzyme B12) concentrations, the aptamer domain changes 
structure such that the anti-anti-RBS stem is interrupted. As a result, the anti-RBS 
stem is formed that sequesters the RBS and prevents association with the 






Previous work, largely involving in-line probing experiments (a method that 
comprises of cleaving RNA molecules under different conditions, for example, with 
or without a potential ligand, and comparing differences in cleavage patterns to see 
whether potential ligands have in fact bound to the RNA to protect it from 
degradation), demonstrates that the riboswitch directly binds B12 and has a 
preference for binding AdoCbl. Some of these experiments even suggest that 
certain B12 types, such as CNCbl, are unable to switch off the riboswitch (Nahvi et 
al, 2002; Nou and Kadner, 2000). This is thought to be due to a requirement for the 
5’-deoxyadenosyl group at the upper ligand position, in order to bind to the B12-
binding pocket and allow structural modulation of the RNA (Nahvi et al, 2002). 
 
Later studies used the same in-line probing technique to compare the binding 
affinities of a wider range of corrinoid compounds and also determine which 
particular region of AdoCbl is responsible for the structural changes undergone by 
the E. coli btuB riboswitch. Findings from these studies indicate that it is the corrin 
ring that is responsible for structural changes within the riboswitch, rather than the 
upper or lower ligand (Gallo et al, 2008), due to the fact that four different B12 
variants (including CNCbl), with varying upper and lower ligands, were all found to 
induce essentially the same conformational changes in the riboswitch structure. 
These studies also indicate that binding to the riboswitch is completely independent 
of whether the molecule is in the “base-on” or “base-off” conformation. However, the 
upper and lower ligands have an important initial role in effectively binding the 
riboswitch and reaching a highly stable complex with the RNA (Gallo et al, 2008), 
demonstrated by the difference in binding affinities of the variants. This role of the 
axial ligands in binding affinity was confirmed in later studies (Gallo et al, 2011).  
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1.5.4 Latest developments in riboswitch research  
In more recent times, researchers have been able to exploit the fundamental 
knowledge acquired on riboswitches in order to design ones with medicinal or 
biotechnological applications. One such example involves the recent synthesis of 
functional riboswitches that are able to detect explosives, due to the design of an 
aptamer domain that is able to bind a component known as 2,4-dinitrotoluene (2,4-
DNT), commonly found in explosives (Borujeni et al, 2015).  
 
In other applications, riboswitches are being utilised as powerful RNA imaging tools 
to elucidate mechanisms such as those underlying the dynamics of the mRNA and 
ncRNA life cycle. Here, researchers developed an RNA imaging tool consisting of a 
cobalamin-linked fluorophore and a B12-riboswitch containing RNA tag (Figure 1.10). 
Within the cobalamin linked fluorophore, cobalamin quenches the fluorescence of 
the fluorophore until cobalamin comes into close proximity with the riboswitch in the 
RNA tag. When cobalamin binds the riboswitch, it is no longer able to quench the 
fluorescence of the fluorophore and therefore the fluorescence can now be detected 







In addition to this, riboswitches controlling key metabolic systems in pathogenic 
organisms can be exploited through the use of metabolite/ligand analogues for the 
development of antibacterial compounds (Blount and Breaker, 2006). These 
advances suggest that the continued discovery and analysis of riboswitches will 
allow progress in creating more useful molecular tools. 
  
Figure 1.10. Diagram representing the use of a B12-dependent riboswitch in 
RNA imaging. RNA imaging tool using a cobalamin-linked fluorophore and a 






1.6 Aims and objectives 
The aim of this thesis is to investigate the possibility of engineering the production 
of B12 variants, through the construction of an empty, metal-free B12 shell, and 
exploring what effect such compounds might have on cellular control elements, 
such as riboswitches. In order to study this, a technique was designed and 
developed that utilises an in vitro system to determine the effect of B12 variants on 
the well-characterised B12-dependent btuB riboswitch. This method allows a quick 
and easy way of testing the ability of B12 variants to directly bind to and deactivate 
the btuB riboswitch, without relying on indirect cellular effects. 
 
The production of such a technique required the construction of a plasmid in which 
the btuB riboswitch was placed upstream of the eGFP reporter gene. This plasmid 
was combined with in vitro transcription/translation machinery in the presence of 
different B12 variants of both natural and unnatural origin, to see how each affects 
the levels of eGFP production. The effects of many of these variants on the 
riboswitch have not yet been well studied. Of these unnatural ligands, AdoRbl is one 
that has previously been suggested to interfere with the riboswitch. However, this 
idea lacked firm evidence (Widner et al, 2016). The idea was investigated in this 
project to determine whether AdoRbl does in fact interfere with the riboswitch, side 
by side with other B12 variants. Should AdoRbl, or any of the other unnatural B12 
analogues, be able to do this will reflect on whether these analogues have 
antivitamin potential (the ability to interfere with and inhibit cellular processes, 
without carrying out the same functions as B12). Thus, the research carried out here 
has the potential to open up an exciting new field of research into the use of B12 
analogues in medical advances and drug design.  
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2.1 Microorganisms and cloning 
2.1.1 Bacterial strains 
Table 2.1. Bacterial strains. 
Strain Genotype Source 
JM109 e14-(McrA-) recA1 endA1 gyrA96 thi-1 
hsdR17 (rK- mK+) supE44 relA1 Δ(lac- 
proAB) [F ́ traD36 proAB lacIqZΔM15] Promega 
MG1655 F-, lambda-, rph-1 Dr Rokas 
Juodeikis 
Rosetta (DE3) F- ompT hsdSB(rB- mB-) gal dcm (DE3) 
pRARE (CamR) Novagen 
DH5a F- φ80 lacZ∆M15 ∆(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rK-,mK+) phoA 
supE44 λ- thi-1 gyrA96 relA1 Thermo Fisher 
NovaF- F- endA1 hsdR17 (rK12- mK12+) supE44 thi-
1 recA1 gyrA96 relA1 lac Novagen 
BL21*(DE3)-
pLysS 
F- ompT hsdSB (rB-, mB-) gal dcm (DE3) 
pLysS (CmR) Novagen 
E. coli ED661 K-12 (DE3); λ− F− rph-1, T7RNAP. All the 
genes for HBAH synthesis were integrated 





2.1.2 Plasmids  
Table 2.2. Plasmids. 
Plasmid Description Source 
pET3a Overproduction vector with T7 promoter, 
AmpR. With added SpeI site Dr Evelyne 
Deery 
pET14b Overproduction N- terminal His6tag 
fusion protein vector with T7 promoter, 
AmpR. With added SpeI site 
Dr Evelyne 
Deery 
cobC-pET14b pET14b with A. vinosum cobC gene Dr Andrew 
Lawrence 
cobD-pET14b pET14b with A. vinosum cobD gene Dr Andrew 
Lawrence 




pET3a with R. capsulatus 
cobAIJFMKLHB genes, B. melitensis 




pETcocoR Modified pETcoco plasmid. Protein 
overproduction vector, regulation of the Dr Rokas 
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copy number with glucose and 
arabinose: dual origins of replication 
control: single-copy (oriS) and medium 
copy (oriV) states, AmpR 
Juodeikis 
eGFP-pET14b pET14b with eGFP gene Dr Matthew 
Lee 
 
2.1.3 Primers  
Table 2.3. Primers. 
Name Sequence Restriction 
Site 
CobP_For CAT CAT ATG ATT GGC GAA AAC GAA AGG NdeI 
CobP_Rev ACT ACT AGT CAG CGA TCG ATG GGA ACG 
 
SpeI 
CobP_Rev2 ATA CTC GAG GCG ATC GAT GGG AAC GCC XhoI 
CobV_For ACT CAT ATG ACA CGA CTC CGC CCA C NdeI 
CobV_Rev ACT ACT AGT CAC TCG ATG AGG ATC GC SpeI 
CobU_For CAC CAT ATG AAC ATG ACG CTC GAC NdeI 
CobU_Rev ACT ACT AGT CAC GCC TCG CTC ACG CC SpeI 
Rib_For GCT TCT AGA GCC GGT CCT GTG AGT TAA TAG G XbaI 
Rib70_Rev GAT CAT ATG CGG AAG ACG GCG CAG CAC NdeI 
Hyb2_For GA TGC TTT ACA ATG AGC AAA GG n/a 
Hyb2_Rev CC TTT GCT CAT TGT AAA GCA TC n/a 
eGFP_Rev AGC ACG CGT CTT GTA GTT CCC GTC MluI 
M_loti_For GCT TCT AGA CCT AAA TCC GCT CCA GAC GGT C 
 
XbaI 
M_loti_Rev GAT CAT ATG GGC CAT GGC TTC GCC GTC GGC 
 
NdeI 
NKDNA_For GTG CCA CCT GAC GTC TAA G n/a 




2.2 Media for growing microorganisms 
2.2.1 Antibiotics 
Table 2.4. Antibiotics. 
Antibiotic Stock concentration Working concentration 
Ampicillin 100 mg/mL in dH2O 100 mg/L 
Chloramphenicol 34 mg/mL in ethanol 34 mg/L 
 
2.2.2 Luria-Bertani (LB) medium 
10 g tryptone, 5 g yeast extract and 5 g NaCl, were made up to 1 L with distilled 
H2O (dH2O). This was then autoclaved (heated to 121°C for 15 minutes in an 
autoclave). 
 
2.2.3 LB agar 
Made up as LB medium, with 15 g technical agar also added. After autoclaving, LB 
agar was cooled to ~50°C and poured into Petri-dishes (~25 mL per plate). For LB 
agar with antibiotics, antibiotics are added after cooling to ~50°C, before pouring. 
 
2.2.4 Mg2+ Stock (2 M) 
2 g MgCl2,6H2O and 2.5 g MgSO4,7H2O were combined before making up to 10 mL 
with dH2O. This was then filter-sterilised. 
 58 
2.2.5 SOC medium  
2 g tryptone, 0.5 g yeast extract, 1 mL 1 M NaCl and 0.25 mL 1 M KCl was made up 
to 100 mL with dH2O. This was then autoclaved. After autoclaving, 1 mL 2 M Mg2+ 
stock (filter-sterilised) and 1 mL 2 M glucose solution (autoclaved) were added. 
2.2.6 10X M9 salts 
60 g Na2HPO4, 30 g KH2PO4, 10 g NH4Cl and 5 g NaCl were weighed out and made 
up to a litre with dH2O before autoclaving. 
 
2.2.7 M9 minimal medium 
100 mL 10X M9 Salts, 20 mL 20% (w/v) glucose (autoclaved), 2 mL 1 M MgSO4 
(filter-sterilised) and 1 mL 0.1 M CaCl2 (filter-sterilised) were combined and made up 
to 1 L with 900 mL autoclaved dH2O. 
 
2.2.8 2YT medium 
16 g tryptone, 10 g yeast extract (YE) and 5 g NaCl, were made up to 1 L with 
dH2O. This was then autoclaved. 
 
2.2.9 M9-YE medium 
50 mL 10X M9 salts, 5 mL 50% glycerol, 5 g YE, 1 mL 1 M MgSO4 and 0.5 mL 0.1 
M CaCl2 were made up to 500 mL with dH2O before autoclaving.  
 59 
2.3 Reagents and protocols for molecular biology 
 
2.3.1 Preparation of competent E. coli cells (DH5α, NovaF-, E. 
coli 661, BL21*(DE3)-pLysS, BL21*(DE3)-pLysS-btuB strains) 
The appropriate bacterial strain was re-streaked from a single bacterial colony onto 
an LB agar plate with the appropriate antibiotics, aseptically, and incubated at 37°C 
overnight.  
40 mL LB medium was inoculated with 1 bacterial colony and grown to OD600 = 0.3. 
This was chilled on ice for 10 minutes before centrifugation at 3000 rpm for 10 
minutes, at 4°C. The pellet was resuspended in 20 mL ice-cold 0.1 M CaCl2 (filter-
sterilised 0.2 µm) and incubated on ice for 20 minutes. Cells are centrifuged again, 
as before, and gently resuspended in 2 mL ice-cold 0.1 M CaCl2/15% glycerol (filter-
sterilised 0.2 µm). Cells were dispensed as 50 µL aliquots into chilled cryotubes, 
flash-frozen on dry ice and stored at -80°C. 
 
2.3.2 Transformation of competent cells  
Competent cells (50 µL) were thawed and 5 µL 0.1 µg/µL plasmid (or ligation 
mixture) added. Cells were incubated on ice for 15 minutes, at 42°C for 90 seconds, 
then immediately on ice for 2 minutes. 200 µL SOC was added, followed by 
incubation at 37°C for 1 hour. Cells were then spread across LB agar plates with 
appropriate antibiotics and grown overnight at 37°C. 
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2.3.3 Preparation of overnight starter cultures 
5 mL LB media is inoculated with a single bacterial colony and antibiotics at their 
appropriate working concentrations, before incubating at 37°C and 160 rpm in a 
shaking incubator, overnight. 
 
2.3.4 Preparation of pETcocoR starter cultures 
5 mL LB medium was inoculated with a single bacterial colony. Ampicillin was 
added at the appropriate working concentration as well as 0.2% glucose in order to 
maintain a low plasmid copy number. This was incubated at 30°C and 160 rpm in a 
shaking incubator, overnight. 
The following day, 100 µL of the starter culture was transferred into a tube of fresh 5 
mL LB (plus ampicillin) and grown at 37°C and 160 rpm in a shaking incubator until 
an OD600 of 0.2-0.4 is reached. 
Once the appropriate OD was reached, L-arabinose was added at a final 
concentration of 0.01% in order to induce multiplication of the pETcocoR copy 
number. This was grown in the same conditions for 4-5 hours before centrifuging at 
3000 rpm for 10 minutes. The pellet can be used for plasmid extraction. 
 
2.3.5 TE buffer 
10 mM Tris-HCl pH 8.0 and 1 mM EDTA were made up to 50 mL with sterile dH2O, 
before autoclaving. 
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2.3.6 Plasmid DNA purification using the QIAprep Spin 
Miniprep Kit (Qiagen) 
Bacterial cells from a starter culture were pelleted via centrifugation at 3000 rpm for 
10 minutes. Plasmid DNA was then purified using the QIAprep Spin Miniprep Kit 
and a microcentrifuge, using the associated kit protocols 
(https://www.qiagen.com/handbooks). However, the final DNA elution stage was 
carried out using 50 µL 1X TE buffer. 
 
2.3.7 DNA amplification using polymerase chain reaction 
(PCR) 
PCR was set up as per Table 2.5. 
Table 2.5. Standard PCR. 
PCR reagents Volumes (µL) 
Fast Start High Fidelity buffer 
x10 (from Sigma) 
5 
DMSO - 
Rib_For Primer @ 10 uM 2 
Rib70_Rev Primer @ 10 uM 2 
dNTPs @ 2 mM 5 
Template 20 
H2O 15 
Fast Start High Fidelity enzyme 
(1U/µL, from Sigma) 
1 
 
Using a PCR machine, samples were heated as follows: 
• 2 minutes at 96°C 
• 20 cycles of: 30 s at 96°C, 30 s at 55°C, and x minutes at 72°C (x = 1 minute 
per 1000 bp). 
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• 7 minutes at 72°C 
2.3.8 Preparation of 1% agarose gels 
0.5 g agarose was dissolved in 50 mL 1X TAE buffer (diluted from commercially 
obtained 50X TAE buffer, from Thermo Scientific) by heating. Once cooled to 
~60°C, 1 drop of ethidium bromide was added before pouring. 
 
2.3.9 Agarose gel electrophoresis 
The agarose gel was covered with 1X TAE buffer. DNA samples were then mixed 
with 6X loading dye (from the Qiagen Miniprep Kit) before 12-20 µL samples were 
loaded alongside 5 µL DNA ladder (Bioline hyperladder 1kb), and run at 140 V for 1 
hour.  
 
2.3.10 DNA purification by centrifugation 
For gel extraction or PCR clean-up, the Qiagen Gel Extraction kit was used and the 
associated standard protocol was followed, with DNA eluted in 30 µL nuclease-free 
H2O.  
2.3.11 Restriction enzyme digest 
5 µL DNA, 1 µL of appropriate 10X buffer and 0.5 µL 10 U/µL restriction enzyme(s), 
also from Promega, were combined in an Eppendorf tube and made up to 10 µL 
(with dH2O) before incubating at 37°C for 60 minutes. 
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2.3.12 DNA ligation 
5 µL 2X ligase buffer (Promega), 2.25 µL 100 ng/µL vector, 2.25 µL 100 ng/µL insert 
and 0.5 µL 10 U/µL T4 DNA ligase (Promega) were combined in an Eppendorf tube 
before incubating at room temperature for 2 hours. 
 
2.3.13 ‘Link and Lock’ multiple cloning strategy 
This method allows the formation of multiple gene constructs by the consecutive 
cloning of genes into the pET3a plasmid, and was developed by Dr. Evelyne Deery 
and Dr. Helen McGoldrick (McGoldrick et al, 2005). This involves creating 
compatible cohesive ends on two different plasmids, using different restriction 
enzymes, which can fuse together to join two or more genes while creating a site 
that can no longer be cleaved by either of the original enzymes.  
 
2.3.14 Test to verify cobalamin production   
Overnight 10 mL LB starter cultures were prepared for each transformant strain. 
After overnight growth, 1 mL samples from each starter were centrifuged (5000 rpm, 
2 minutes) and the supernatant removed. The pellet can then be checked for colour 
indicating cobalamin production by bacterial cells.  
 
2.3.15 In vitro transcription/translation using the PURExpress 
in vitro protein synthesis kit 
Plasmid DNA samples were prepared as normal, except that they were eluted in 25 
µL EB buffer instead of 50 µL TE buffer. The lower elution volume allows the DNA 
samples to be more concentrated (150 ng/µL as per measured on a NanoVue 
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spectrophotometer), and the use of EB buffer allows them to be free of EDTA 
(which is thought to interfere with the protein synthesis kit components). Within the 
25 µL reaction, there is a 2.5 µL allocation for nuclease-free water that can be 
substituted with cobalamin in order to investigate its effect on eGFP production and, 
in turn, on the riboswitch. 
 
Reactions were prepared and undergone as per the associated kit protocol: 
1. The necessary number of aliquots of solutions were thawed on ice. They were 
then centrifuged in a microfuge to collect solutions to the bottom of tubes. 
2. The reactions were assembled on ice in a new tube in the following order:  
• 10 µL Solution A 
• 7.5 µL Solution B 
• 2.5 µL Nuclease-free H2O (or B12 variant substitute) 
• 5 µL 150 ng/µL Template (plasmid) DNA containing a T7 promoter and 
T7 terminator 
3. The reaction was mixed and then centrifuged in a microfuge.  
4. The samples were incubated at 37°C for 4 hours.  
5. The reaction was stopped by placing the tube(s) on ice. 
6. The samples were used directly for analysis or frozen at –20°C for use at a later 
time.  
 
Once the reactions were complete and ended by incubation on ice, 20 µL of 
reaction mix was removed and combined with the same volume of 2X Laemmli SDS 
buffer, before boiling for 5 minutes. Samples of 10 µL were then loaded onto a 
12.5% SDS PAGE for analysis using SDS-PAGE. 
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2.3.16 Reverse riboswitch growth assays 
Assays were set up in 5 mL minimal medium using transformants carrying one of 
each of the two plasmid variants. Each transformant was grown in two different 
conditions with each carried out in duplicate.  
 
Following overnight growth, pellets were resuspended in 1 mL H2O and boiled for 
15 minutes to break open the cells. 200 µL samples were then removed and 
prepared for SDS-PAGE analysis. SDS-PAGE analysis was then carried out in 
order to compare eGFP levels in each sample. 
 
2.3.17 Adenosylation of Cbi using BtuR 
The assay was prepared in a universal Falcon tube using the following components; 
100 µM Cbi, 1 mM ATP, 2.5 mM MnCl2, 63 µM BtuR and 10 mM NaBH4, before 
making up to a volume of 20 mL with PD10 buffer. The Falcon tube was then 
wrapped in foil, due to the light sensitivity of AdoCbi and to prevent removal of the 
adenosyl group soon after AdoCbi is made. This was then incubated overnight in a 
glove box. 
2.3.18 ‘In vivo’ CobP activity assay 
BL21*(DE3)-pLysS-btuB_CDPVU-pET3a colonies were used to set up 2 different 
50 mL LB cultures (with the appropriate antibiotics), and cells were grown at 37°C 
for 5 hours in a shaking incubator at 180 rpm, in the dark.  
 
Following 5 hours of growth, dicyanocobinamide (obtained from Sigma-Aldrich) was 
added to the cultures at a final concentration of 100 pM.  
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After 2 hours of growth in the presence of dicyanocobinamide, protein production 
was induced with the addition of 0.4 mM IPTG and the cultures left to incubate 
overnight; one at 37°C and the second at 19°C. 
 
On the following day, both cultures were centrifuged at 4000 rpm for 15 minutes in 
order to separate the supernatant and pellet. Samples were taken from both 
supernatants for analysis using HPLC-MS. In regards to the pellets, both were 
initially resuspended in 100 µL H2O before the addition of 400 µL methanol (as 
cobalamin is soluble in methanol). These were then heated to 60°C, under a fume 
hood, for 15 minutes before centrifuging at 13000 rpm for 1 minute. The resulting 
supernatants were then removed and dried down in a vacuum centrifuge in order to 
remove all traces of methanol before running samples on a HPLC-MS instrument. 
Once dried down, they were resuspended in 100 µL ultra-pure H2O for analysis 
using HPLC-MS.  
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2.4 Reagents and protocols for biochemistry 
2.4.1 Solutions for immobilised metal ion affinity (IMAC) 
Charge buffer - 50 mM NiSO4 
Binding buffer - 20 mM TRIS-HCl pH 8.0, 500 mM NaCl, 5 mM imidazole 
Wash buffer I - 20 mM TRIS-HCl pH 8.0, 500 mM NaCl, 50 mM imidazole 
Wash buffer II - 20 mM TRIS-HCl pH 8.0, 500 mM NaCl, 100 mM imidazole 
Elution buffer - 20 mM TRIS-HCl pH 8.0, 500 mM NaCl, 400 mM imidazole 
Strip buffer - 20 mM TRIS-HCl pH 8.0, 500 mM NaCl, 100 mM EDTA 
PD10 buffer - 20 mM TRIS-HCl pH 8.0, 100 mM NaCl 
 
2.4.2 Recombinant protein production 
Day 1: E. coli BL21*(DE3)-pLysS cells were transformed with a plasmid containing 
a gene for the recombinant protein of interest and an antibiotic resistance marker. 
 
Day 2: A 10 mL LB starter culture was prepared. 
 
Day 3: 1 L autoclaved LB was inoculated with the 10 mL starter culture and 
appropriate antibiotics were added at working concentrations. The flask was then 
incubated at 37°C and 160 rpm, until the bacteria reached an OD600 of 0.6. Once 
this OD600 of 0.6 was reached, 400 µM IPTG was added and the culture was 
incubated at 19°C and 160 rpm, overnight. 
 
2.4.3 Recombinant protein purification 
Following the steps in 2.4.2, bacterial cells were collected by centrifugation at 4000 
rpm for 20 minutes at 4°C. The bacterial pellet was then resuspended in 30 mL 
binding buffer. The cells were then transferred to a sonication vessel before 
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sonicating using a Sonics Vibracell Ultrasonic processor using the following 
settings:  
 
• Timer – 6 minutes 
• Pulse – 30 seconds on / 30 seconds off 
• Amplitude – 50% 
 
Following sonication, the cells were centrifuged at 18000 rpm for 20 minutes at 4°C 
to separate the cell debris (pellet) from the soluble fraction (supernatant). The 
protein of interest was then purified from the supernatant, using IMAC.  
 
Preparation of nickel column: 
An empty column was fitted with a filter before adding 5 mL Chelating SepharoseTM 
resin. This was allowed to set before charging with 15 mL charge buffer. The 
column was then equilibrated with 20 mL binding buffer. 
 
Purification of protein: 
Supernatant was loaded onto the column. The column was then washed with 20 mL 
binding buffer, followed by 10 mL wash buffer I and 5 mL wash buffer II. The protein 




The resin was then regenerated by running through 15 mL of strip buffer and 
washing with 50 mL dH2O. 
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2.4.4 Semi-quantitative BioRad assay 
Using the BioRad assay, it can be seen which of the elutions contain the majority of 
the protein. Drops containing 10 µL H2O and 5 µL Biorad reagent were prepared per 
protein sample. 5 µL of protein solution, from each of the elutions, was added to 
each of the Biorad assays. The more the Biorad reagent changes from red to blue, 
the more protein is present in the sample. The two samples that contained the most 
protein were combined. 
 
2.4.5 Buffer exchange using PD10 column (GE Healthcare) 
The column was equilibrated with 25 mL PD10 buffer, before loading on 2.5 mL of 
purified protein. The flow-through was discarded. 3.5 mL PD10 buffer was then 
added and the flow-through (containing protein) was collected. 
 
2.4.6 A280 protein concentration estimation using the 
extinction coefficient 
The protein concentration can be estimated using the Beer-Lambert law:  
Concentration (M) = A280 / protein’s extinction coefficient (e value) 
e values used: 
CobU – 12490 Lmol-1cm-1 
CobP – 37470 Lmol-1cm-1 




2.4.7 2X Laemmli SDS buffer 





Volume required to 
make up 10 mL 
Tris-HCl pH 6.8 0.5 M 0.125 M 2.5 mL 
Glycerol 100% 20% 2 mL 
SDS 10% 4% 4 mL 
b-mercaptoethanol 100% 10% 1 mL 
Bromophenol blue 0.08% 0.004% 0.5 mL 
 
2.4.8 1X Running buffer 
288 g glycine and 60 g Tris were made up to 2 L with dH2O, to prepare 10X running 
buffer. For the preparation of 1X running buffer, 100 mL 10X running buffer was 
combined with 10 mL 10% SDS and made up to 1 L with dH2O. 
 
2.4.9 Coomassie blue stain 
250 mL 100% trichloroacetic acid (TCA), 0.6 g Coomassie blue R, 0.1 g SDS, 0.25 
g trizma base, and 0.1 g glycine were combined and made up to 500 mL with dH2O. 
 
2.4.10 Analysis of recombinant protein by SDS-PAGE 
(polyacrylamide gel electrophoresis) 
 
Protein samples were collected, mixed with equal volumes of 2X Laemmli SDS 




Table 2.10. SDS gel recipe. 
Resolving Gel: 12.5% 15% Stacking Gel: 5% 
dH2O (mL) 3.4 2.2 dH2O (mL) 3.4 
30% acrylamide (mL) 6.3 7.5 30% acrylamide (mL) 1.5 
1.5M Tris-HCl pH 8.8 
(mL) 
3.8 3.8 0.5M Tris-HCl pH 6.8 (mL) 1.9 
10% SDS (mL) 1.5 1.5 10% SDS (mL) 0.75 
10% APS (mL) 0.15 0.15 10% APS (mL) 0.075 
TEMED (mL) 0.01 0.01 TEMED (mL) 0.01 
 
Gels were run in running buffer at 200 V for 1.5 hours and stained with Coomassie 
blue stain. Gels were de-stained overnight in dH2O, under gentle agitation. 
 
2.4.11 Transfer buffer 
100 mL 10X running buffer was combined with 200 mL 100% methanol and made 
up to 1 L with dH2O. 
 
2.4.12 Blocking solution 
5% (w/v) non-fat dried milk in PBS. 
 
2.4.13 Phosphate-free blocking solution 
5% (w/v) nonfat dried milk, 150 mM NaCl, 50 mM Tris-HCl pH 7.5, made up with 30 
mL dH2O. 
 
2.4.14 Western blot analysis 
Samples were initially run on SDS-PAGE (as described in 2.5.10). However, instead 
of staining on completion, gels were rinsed in transfer buffer for 5 minutes. Western 
blot apparatus was set up and run for 1 hour at 100 V.  
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Once protein was transferred onto the nitrocellulose membrane, this was then 
covered in blocking solution and incubated for 2 hours at room temperature, on a 
platform shaker. 
 
Blocking solution was then discarded and the membrane was immediately 
incubated with the appropriate primary antibody (1:1000 dilution in PBS), for 2 hours 
at room temperature, on a platform shaker.  
 
The membrane was then washed in PBS for 10 minutes, 3 separate times. 
Following this, the membrane was equilibrated in a buffer containing 150 mM NaCl 
and 50 mM Tris-HCl, before incubating for 1 hour in enzyme-coupled secondary 
antibody (1:5000 dilution in phosphate-free blocking solution). 
 
The membrane was then washed in phosphate-free blocking solution for 10 
minutes, 3 separate times. Following this, incubation in substrate 5-bromo-4-chloro-




Mouse monoclonal anti-polyHistidine antibody (Sigma Aldrich) 1:1000 
Mouse anti-GFP antibody (Sigma Aldrich) 1:1000  
Anti-mouse IgG (H+L), AP Conjugate (Promega) 1:5000 
Rabbit anti-TetR antibody (Sigma Aldrich) 1:1000 
Goat anti-rabbit IgG (H+L) secondary antibody, AP, Invitrogen 1:5000 
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2.4.16 Digestion buffer 
10 mM NH4HCO3, 10% acetonitrile in dH2O. 
2.4.17 Gel filtration chromatography 
Gel filtration chromatography was carried out using an Äkta FPLC system. Samples 
were resolved on a SuperdexTM 200 10/300 GL column (GE Healthcare) which 
was equilibrated in 20 mM Tris HCl, pH8, 100 mM NaCl. A 1 mL protein sample was 
loaded onto the column and run at a flow rate of 0.5 mL/min. Calibration of the 
column was achieved using the MWGF-1000 gel filtration molecular weight marker 
kit from Sigma (Table 2.11). 
Table 2.11. Sigma molecular weight marker kit components. 








β-amylase, sweet potato 200 4 
Apoferritin, horse spleen 443 10 
Thyroglobulin, bovine 669 8 
Blue dextran 2000 2 
 
 
2.4.18 Reverse phase chromatography (on an RP18 column) 
LiChroprep RP18 resin from Merck was activated in hexane before washing with 
ethanol 3 times. Activated resin was then poured into an appropriate column, as 
required, before washing with acetonitrile and equilibrating with 0.1% TFA. Prior to 
application of the sample, samples must be acidified using 0.5 M HCl to a pH below 
4. The sample is then applied and the column washed with 0.1% TFA. Bound 




2.4.19 High performance liquid chromatography (HPLC) 
Samples were run through a HPLC (Agilent 1100 system) using the following 
method:  
• Column: Ace 5 AQ (2.1 x 250 mm; 5 µM; 100 Å) 
• Column temperature: 30°C 
• Flow rate: 0.2 ml min-1 
• Solvent A: 0.1% TFA 
• Solvent B: Acetonitrile 
Table 2.12. HPLC gradient method. 








2.5.20 Electrospray ionization (ESI) - mass spectrometry (MS) 
Samples were run through the HPLC column, before analysing by ESI-MS using a 
Bruker MicroTOF-QII machine. ESI-MS involves the application of a high voltage to 
samples, in order to produce an electrospray of ions which can be used to obtain a 
mass spectrum. 
 
2.4.21 Preparation of crystallisation screens 
Protein crystallisation was attempted using the hanging drop method. 24-well 
crystallisation trays were greased for the screening process. Initial screens for each 
protein involved the use of conditions from Molecular Dimensions Structure Screens 
1 and 2. 500 µL of each condition were pipetted into each well. On top of a 
siliconized glass coverslip, 1 µL of each condition was pipetted down followed by 1 
µL of protein sample directly on the condition drop. The reservoir was then sealed 
 75 
with the coverslip corresponding to that condition, such that the drops are facing 
down. Once the required number of wells was complete, the trays were incubated at 
19°C and drops were observed periodically under a light microscope for the 
presence of crystals, nucleation or precipitation. A 1:3 ratio was used for 
protein:substrate mixes. 
 
2.4.22 Optimisation screens 
Table 2.13. Optimisation screen of condition 8 (SS2). Component 
optimised: MPD (2-methyl-2,4-pentanediol). 
Tray 1 1 2 3 4 5 




























































Tray 2 1 2 3 4 5 
































































Table 2.14. Optimisation screen of condition 25 (SS2).  
Tray 1 1 2 3 4 5 6 









































































Table 2.15. Finer optimisation screen of condition 8 (SS2). Component 
optimised: MPD (2-methyl-2,4-pentanediol). 
Tray 1 1 2 3 4 5 6 








































































Tray 2 1 2 3 4 5 6 









































































Table 2.16. Optimisation screen of condition 14 (SS1). Components optimised: 
Na/Caco (sodium cacodylate) and PEG (polyethylene glycol). 
 



























































































































Table 2.17. Optimisation screen of condition 15 (SS1). Components optimised: 
Na/Caco (sodium cacodylate), Mg/Ace (magnesium acetate) and PEG 
(polyethylene glycol). 


























































































































Table 2.18. Optimisation screen of condition 30 (SS1). 






















































2.4.23 X-Ray diffraction experiment 
Crystals were picked on a loop and dipped into the cryo-protectant consisting of the 
corresponding well solution and 25% glycerol (w/v), before vitrification by 
transferring into a 100 K nitrogen stream. This procedure was done by Marie 
Anderson. Vitrified crystals were then taken to Synchroton radiation source 
(Diamond Light Source, Oxfordshire, UK) where datasets were collected. 
 
2.4.24 eGFP fluorescence analysis 
Fluorescence intensities from in vitro reaction samples were measured, using a 
Perkin Elmer Luminescence Spectrometer LS50B. Excitation and emission 
wavelengths of 488 nm and 510 nm were used, respectively, in order to obtain 
fluorescence intensity values from each sample. These values were then used to 
work out eGFP concentrations, relative to a standard curve prepared from the 





• Photomultiplier tube (PMT) voltage – 900 V 
• Slit width – 10 mm round 
• Averaging time – 0.5 s 
 
 
2.4.25 CobP in vitro assays 
Purified CobP protein (variable concentration) was combined with 1 M MgCl2, 14 
mM GTP or 20 mM ATP, and a cobinamide of choice (variable concentration) 
before making up to a final volume of 100 µL with pH 8 PD10 buffer and incubating 
in the dark overnight.  
 
On the following day, each assay was heated at 60ºC for 10 minutes to denature all 
protein, before centrifuging at 13000 rpm for 5 minutes. 100 µL samples were 
removed for analysis using HPLC-MS. 
 













1 - 5 2 - 41.4 - 
2 - 5 2 - - 50 
3 - 5 - 2 41.4 - 
4 - 5 - 2 - 50 
5 0.6 5 - - 41.4 - 
6 0.6 5 - - - 50 
7 0.6 5 2 - 41.4 - 
8 0.6 5 2 - - 50 
9 0.6 5 - 2 41.4 - 
10 0.6 5 - 2 - 50 
 
 













1 6 5 2 20 - 8 
2 6 5 2 - 20 8 
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3 6 5 2 20 - 9 
4 6 5 2 - 20 9 
 















1 Av P 60 5 2 10 - 
4 Av L 60 5 2 10 - 
7 Rc P 6 5 2 10 - 
10 Rc L 6 5 2 10 - 
13 Av P 60 5 2 10 10 
16 Rc P 6 5 2 10 10 
 















1 Av P 600 5 2 10 - 
2 Av L n/a 5 2 10 - 
Controls:        
3 - - - 5 2 10 Yes 
4 Av P 600 5 2 10 Yes 











As a consequence of over half a century of B12 research it is now possible to 
persuade E. coli to make B12 through metabolic engineering, a compound it cannot 
make on its own. It has also been discovered that certain organisms, such as A. 
vinosum, have the ability to produce cobalt-free corrinoids when grown in low cobalt 
conditions (Toohey, 1965). One of the aims of this project was to see whether it 
would be possible to combine these two key factors, the ability to recombinantly 
produce complex molecules in E. coli with the ability of A. vinosum enzymes to 
produce cobalt-free corrinoids. The goal therefore was to be able to produce cobalt-
free corrinoids, including cobalt-free cobalamin (hydrogenobalamin), in E. coli. This 
can then be used as the starting point for creating unnatural B12 variants that act as 
B12 antagonists or inhibitors, especially if they have different transition metals 
inserted into the empty corrin framework. These metal variants of cobalamin 
(metbalamins), have a very similar structure to cobalamin and will likely interfere 
with B12-dependent processes within the cell, thereby acting as B12 inhibitors.   
 
To achieve such a goal, the construction of a plasmid containing a gene set 
encoding enzymes that together have the capacity to make hydrogenobalamin was 
attempted. In order to do this certain B12 biosynthesis genes, cobQ, cobC, cobD, 
cobP, cobV and cobU, were amplified from the A. vinosum genome. These 
particular genes were chosen for a number of reasons. cobQ was chosen to be 
amplified from the A. vinosum genome because the enzyme, when taken from 
standard aerobic organisms, is known to recognise ado-cobyrinic acid a,c-diamide 
as its substrate (Crouzet et al, 1991), whereas A. vinosum CobQ is able to use 
HBAD as its substrate (Lawrence et al, 2018). The rest of the chosen genes all 
have gene products which are involved in the synthesis and assembly of the lower 
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loop, following the cobalt chelation stage, and since A. vinosum is one of the few 
bacteria capable of producing metal-free corrinoids (Toohey, 1965), as discussed in 
Chapter 1, it is thought that the enzymes from this bacterium should be able to 
successfully work with metal-free substrates. 
 
Following the amidation of ado-cobyrinic acid a,c-diamide by CobQ, CobC and 
CobD work together to carry out the synthesis and attachment of the aminopropanol 
linker. Next, the bifunctional enzyme, CobP, initiates the process of assembling the 
lower loop by converting AdoCbi into AdoCbi-GDP. The final stage involves lower 
ligand synthesis and assembly, and requires two enzymes, CobU and CobV, to 
form AdoCbl from AdoCbi-GDP. CobU carries out the synthesis of the lower loop (α-
ribazole phosphate), and CobV assembles this onto AdoCbi-GDP to form AdoCbl 
(Warren et al, 2002). These steps are outlined in greater detail in Chapter 1 (Figure 
1.4).  
 
The work described in this chapter was focussed on attempting to generate new 
metal-free intermediates through the cloning and recombinant expression of the 








































































































































Figure 3.1. The conversion of uroporphyrinogen III to hydrogenobalamin. 
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3.2 Results 
3.2.1 Amplification of B12 biosynthesis genes, involved in the 
synthesis and attachment of the lower loop of B12 
 
The A. vinosum cobQ, cobC and cobD had been previously amplified from the A. 
vinosum genome (by Dr. Emi Nemoto-Smith and Dr. Andrew Lawrence), meaning 
that cobP, cobV and cobU still had to be cloned. The final three genes were 
amplified by PCR, as described in Chapter 2, with varying concentrations of DMSO. 
During amplification, an NdeI site was introduced at the 5’ end of each gene and an 
SpeI site at the 3’ end, via use of the appropriate forward and reverse primers 
(Table 2.3). Introduction of these restriction sites allowed them to be cloned into 
individual pET3a vectors following PCR, and for them to subsequently be cloned 
consecutively within a single plasmid using the ‘Link and Lock’ multiple cloning 
strategy, a method developed by Dr. Evelyne Deery and Dr. Helen McGoldrick 
(McGoldrick et al, 2005). 
 
Agarose gel electrophoresis was used to separate the amplified DNA bands from 
each of the individual PCR samples. The PCR bands from the 2 µL DMSO samples 
(~562 bp cobP, ~754 bp cobV and ~1057 bp cobU), (Figure 3.2), were each cut out 




















C) Marker cobU PCR (2 µL DMSO) cobU PCR (4 µL DMSO) 
 














The three DNA fragments were digested with NdeI and SpeI restriction enzymes, to 
allow for ligation with NdeI and SpeI cut pET3a. Transformation of E. coli JM109 
was carried out using the new ligation product. Plasmid was extracted from 
successful transformants (as described in Chapter 2, Section 2.3.6) and was sent 
for sequencing to ensure that the relevant genes had been successfully amplified 
and cloned into pET3a.  
 
Five of the six required A. vinosum genes were cloned into the same plasmid to 
generate a cobCDPVU-pET3a construct using the ‘Link and Lock’ multiple cloning 
Figure 3.2. Agarose gel electrophoresis showing PCR products from the 
amplification of A. vinosum genes. PCR samples for; A.) cobV B.) cobP C.) 
cobU. Successful PCR bands are seen in the 2 µL DMSO samples (~562 bp 
cobP, ~754 bp cobV and ~1057 bp cobU), and certain 4 µL DMSO samples. 
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strategy, (McGoldrick et al, 2005). Initially, cobC and cobD were cloned together via 
‘Link and Lock’ into pET3a to give cobCD-pET3a. Similarly, cobP and cobV were 
also cloned together to give cobPV-pET3a. Following this, the cobCD genes were 
removed and cloned next to the cobPV genes in the cobPV-pET3a vector, to 
generate cobCDPV-pET3a. Finally, cobCDPV-pET3a was digested with SpeI and 
EcoRI to allow the cloning of cobU via ‘Link and Lock’ to give cobCDPVU-pET3a, 
the five gene plasmid containing the A. vinosum genes required for synthesis of the 
lower loop of B12. The plasmids generated during this investigation were also used 
to allow a study of the individual encoded proteins.  
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3.2.2 Characterising the lower loop enzymes using 
recombinant protein production and purification methods 
 
To determine whether the A. vinosum cobD, cobP, cobV and cobU genes allow for 
recombinant protein production, each of these four genes was cloned individually 
into pET14b using the restriction enzymes NdeI and SpeI. This generated four new 
plasmids; cobD-pET14b, cobP-pET14b, cobV-pET14b and cobU-pET14b. 
Transformation of E. coli BL21*(DE3)-pLysS competent cells was carried out using 
each of the individual plasmids. 
 
Recombinant protein production and protein purification, using IMAC, were 
undertaken (as described in Chapter 2, Section 2.4.2 and 2.4.3) in order to 
demonstrate whether the proteins, encoded by each of the newly amplified A. 
vinosum genes, had been overproduced and whether they were soluble. Previous 
work, by Dr. Andrew Lawrence, showed that A. vinosum CobC expresses well and 
is found in the soluble fractions.  
 
The first two proteins that were investigated, CobP and CobU, have expected 
masses (including the His tag) of 22.5 kDa and 39.1 kDa, respectively. Fractions 
from the purifications of CobP and CobU were analysed using SDS-PAGE, with 
results suggesting both proteins are soluble (Figure 3.3). Bands of the correct size 
are seen for CobP in not only the elution fractions, but also in the total, supernatant 
and flow-through fractions (Figure 3.3). 
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CobV and CobD purification fractions were analysed in the same way, using SDS-
PAGE. Including the His-tag, CobV and CobD are predicted to have masses of 28.8 
kDa and 37.2 kDa, respectively. However, following recombinant protein production 
and purification from E. coli BL21*(DE3)-pLysS, proteins of this size were not 
detected on an SDS gel in either the soluble or insoluble fractions (Figure 3.4).  
  
Figure 3.3. SDS-PAGE analysis of A) CobP (22.5 kDa) and B) CobU (39.1 kDa) 
purifications. CobP and CobU are visible in the elutions. (M – marker, T- total, S – 
supernatant, P – pellet, FT – supernatant flow-through, BB – binding buffer, W1 – 
wash buffer 1, W2 – wash buffer 2, E3 – elution 3, E4 – elution 4, PD10 – PD10 
elution.) 
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In another attempt to detect whether CobV was being produced, the protein 
purification was re-attempted in the presence and absence of 50 mg/mL CNCbl. 
This was done so that any CobV present within the bacterial cells could bind to the 
CNCbl. The strongly coloured nature of CNCbl should then allow easier detection of 
CobV. Unfortunately, CobV was still not detected, with no difference between 
fractions from both sets of purifications (with and without CNCbl), suggesting that it 
was not being overproduced. 
 
Since both CobD and CobV could not be detected, the cobV-pET14b and cobD-
pET14b plasmids were individually transformed into Rosetta competent cells (an E. 
Figure 3.4. SDS-PAGE analysis of fractions from the purification of CobV 
and CobD from E. coli BL21*DE3-pLysS.  A) CobV protein (28.8 kDa with the 
His tag) purification, B) CobD protein (37.2 kDa with the His tag) purification. 
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coli BL21(DE3) derivative designed to enhance the expression of proteins that 
contain codons rarely used in E. coli), supplied by Novagen. This meant that if the 
A. vinosum cobV or cobD genes contain rare codons, for which there are no 
appropriate anti-codons in E. coli BL21*(DE3)-pLysS, then this would no longer be a 
problem since Rosetta contains anti-codons to the rare codons. Bacterial cells were 
cultured, harvested and the protein purification process was repeated. Fractions 
were analysed using SDS-PAGE (Figure 3.5). 
 
 
  CobV-Rosetta CobV-BL21*(DE3)-pLysS 
CobD-Rosetta CobD-BL21*(DE3)-
pLysS 









From the SDS-PAGE analysis, it appeared that the two proteins were still not being 
overproduced and therefore the presence of rare codons was not the problem. A 
western blot analysis was therefore undertaken to see if either protein, CobV or 
CobD, could be detected as a result of their His-tags. No bands were seen within 15 
minutes of developing, although bands were detected in the CobV sample after 
overnight development. However, the bands were smaller than the expected size of 
28.8 kDa (Figure 3.6). The smaller bands could be due to some form of degradation 
Figure 3.5. SDS-PAGE comparing purification fractions from Rosetta and 
BL21*(DE3)-pLysS strain E. coli for CobV (28.8 kDa with the His tag) and 
CobD (37.2 kDa with the His tag). Neither protein is seen to be overproduced. 
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of the protein or, alternatively, could represent some form of background reaction 
and not be CobV at all. No bands were detected in the CobD sample (Figure 3.6). 
 
 
















Despite further attempts at recombinant protein production and purification of both 
proteins, the western blot results remained the same with a smaller than expected 
band for CobV and no bands for CobD. For CobD it is highly likely that the protein is 
not being made by the cells. However, the results remain inconclusive for CobV and 
it is not clear whether the observed band is actually CobV.  
 
As numerous attempts of trying to detect CobD were unsuccessful, it was thought 
that perhaps it may be due to the particular location of the His-tag on the protein 
that was affecting its ability to bind to the nickel column. It could be that while the 
His-tag was at the N-terminus, it was being folded within the protein in such a way 
Figure 3.6. Western blot analyzing insoluble (T), soluble (S) and elution (E) 
fractions from CobV and CobD purifications (from both E. coli BL21*DE3-
pLysS and Rosetta). Bands can be seen in the CobV samples, however, these 




that it was not easily accessible. Therefore, cobD-pET23b (provided by Dr. Andrew 
Lawrence) was used for the transformation of E. coli Rosetta and cultured. By 
placing the gene in a pET23b vector, the resultant gene product should have a C-
terminal His-tag. In this case, CobD should now have a His-tag at the C-terminus of 
the protein which may perhaps be more accessible by the nickel column.  
 
Protein purification was carried out and fractions analysed using SDS-PAGE. 
However, despite the change in the position of the His-tag, CobD was still not 
detected by SDS-PAGE. Therefore, samples from this purification were analysed on 
a western blot alongside samples from the purification of N-terminal His-tagged 
CobD from E. coli Rosetta. No bands were seen on the western blot, suggesting 
that the A. vinosum CobD protein is not being produced. This was repeated several 
times yet the results remained the same.  
 94 
3.2.3 Generation of a plasmid for the production of cobalt-
free B12 (hydrogenobalamin) 
 
The cobCDPVU gene set was required to be cloned into a plasmid containing all of 
the remaining B12 biosynthesis genes needed for the production of 
hydrogenobalamin. These include the cobAIG*JFMKLHBQ(Alv) genes, found in the 
cobAIG*JFMKLHBQ(Alv)-pET3a plasmid (see Table 2.2). Cloning of cobCDPVU into 
this plasmid was attempted through use of the ‘Link and Lock’ strategy.  
 
Numerous cloning attempts were made to obtain the 
cobAIG*JFMKLHBQ(Alv)[CDPVU](Alv)-pET3a plasmid. However, this was not 
successful.  This was most likely due to the desired plasmid being too large, at over 
20000 bp, causing reduced transformation efficiency. A new strategy was therefore 
attempted using a more stable pETcoco variant plasmid, pETcocoR (see Table 2.2). 
cobAIG*JFMKLHBQ(Alv) genes were cloned out of pET3a and into pETcocoR to give 










Figure 3.7. New cloning strategy. The cobAIG*JFMKLHBQ(Alv) genes were 




E. coli BL21*(DE3)-pLysS was transformed with the new cobAIG*JFMKLHBQ(Alv)-
pETcocoR plasmid and cultured in 2YT, in order to test whether the plasmid allows 
for the production of hydrogenobyric acid (HBAH). Cells were first boiled to break 
them apart and then centrifuged in order to separate the cell debris from the 
supernatant. Next, the supernatant was collected and desalted on an RP18 column 
(as described in Chapter 2, Section 2.4.18), a process based on reversed-phase 
chromatography, in order to obtain HBAH. Any HBAH (orange-coloured) present 
was eluted with 50% ethanol. The RP18 elution was vacuum centrifuged to remove 
ethanol from the sample. A sample of 20 µL volume was removed and run on a 
20% acrylamide gel, against hydrogenobyrinic acid (HBA) and hydrogenobyrinic 
acid a,c-diamide (HBAD) standards. Although there appeared to be HBAH present 
in the RP18 elution sample, the molecule did not appear very pure, containing a 
mixture of amidated HBA forms including hydrogenobyrinic acid monoamide 





















Figure 3.8. HBAH purification sample run on 20% acrylamide gel against HBA 
and HBAD standards, seen by the two brightest bands in the HBA and HBAD 
lanes, respectively. The HBAH-containing RP18 elution was run against HBA and 
HBAD standards. HBAH, which is uncharged and therefore does not travel down 
the gel, was found to be present in the RP18 elution sample. This suggests that the 
bacteria are able to successfully make HBAH. However, the mixture is not very 
pure, containing other amidated HBA forms including HBAM and HBAD.  
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Since it was confirmed that the cobAIG*JFMKLHBQ(Alv)-pETcocoR plasmid allowed 
the production of HBAH, attempts were made to insert cobCDPVU into the new 
cobAIG*JFMKLHBQ(Alv)-pETcocoR plasmid, such that the gene products of the 
cobCDPVU genes could allow for the production of hydrogenobalamin from HBAH. 
However, the cobAIG*JFMKLHBQ(Alv)[CDPVU](Alv)-pETcocoR plasmid could not be 
constructed. This could either be due to a failure in the ligation of both DNA 
fragments or due to problems at the transformation stage, despite the use of various 
different competent bacterial cells (JM109, DH10b and NovaF-). In either case, a 
lack of success was most likely due to the desired plasmid being too large, at over 
28000 bp, causing reduced ligation and transformation efficiency.  
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3.2.4 Use of an alternative method to generate 
hydrogenobalamin 
 
As it was not possible to construct a single plasmid that encoded all the enzymes 
for hydrogenobalamin production, an alternative method was investigated. This 
involved the use of a genetically engineered E. coli strain (ED661), developed by 
Dr. Evelyne Deery, in which certain B12 biosynthesis genes have been integrated 
into the E. coli genome. E. coli ED661 contains the cobAIG*JFMKLH-BAlvQAlvE* 
genes (with cobG* and cobE* from Brucella melitensis, and cobB and cobQ from A. 
vinosum) under the control of the T7 promoter. E. coli ED661 also contains the T7 
RNA Polymerase (T7RNAP) gene under the control of the lactose promoter (PLac). 
Together, the integrated genes are capable of producing HBAH, as is the 
cobAIG*JFMKLHBQ(Alv)-pETcocoR plasmid that could not be combined with 
cobCDPVU-pET3a. It is for this reason that E. coli ED661 was used for the 
preparation of ultra-competent cells and transformed with cobCDPVU-pET3a, with 
the expectation that it becomes capable of producing hydrogenobalamin. 
Additionally, E. coli BL21*(DE3)-pLysS was transformed with btuF-pET14b, a 
plasmid containing the btuF gene, in order to overproduce a His-tagged form of the 
B12-binding protein, BtuF, which binds various different corrinoids (Lewinson et al, 
2010). This His-tagged BtuF was then be used to purify corrinoids on a nickel 
column. 
 
E. coli ED661-cobCDPVU-pET3a was cultured in 1 L 2YT medium, from an initial 
10 mL LB medium starter culture, with added ammonium chloride (1 g/L). 
Meanwhile, E. coli BL21*(DE3)-pLysS-btuF-pET14b was cultured in 1 L LB medium, 
from an initial 10 mL LB medium starter culture.  
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Both cultures were harvested and cells were lysed. After cell lysis, both pellets were 
combined together in order that BtuF would bind to all of the corrinoids produced by 
E. coli ED661-cobCDPVU-pET3a. The sample was applied onto a charged nickel 
column to allow the His-tagged BtuF protein to bind to the column, thereby allowing 
all corrinoids to be separated from the remaining sample. Once all the sample was 
run through the column, BtuF was denatured using 8 M urea in order to allow any 
corrinoids to be released and eluted from the column. The elution obtained from the 
E. coli ED661-cobCDPVU-pET3a bacterial pellet was collected.  
 
Similarly, the supernatant from the E. coli ED661-cobCDPVU-pET3a bacterial 
culture was also combined with a BtuF containing pellet and the same procedure 
carried out to obtain another corrinoid mix. Both elutions, from the pellet and 
supernatant, were desalted on an RP18 column. Samples were eluted in 50% 
ethanol and dried down using a vacuum centrifuge. The samples were resuspended 
in 100 µL 0.1% TFA before analysis using HPLC-MS (Chapter 2, Sections 2.4.19 
and 2.4.20). 
 
The HPLC-MS detected one major peak in the chromatogram of both the bacterial 
cell pellet elution sample and the supernatant sample. The mass spectrum of each 
of these peaks both show the same results (Figure 3.9), in which two distinct peaks 
can be seen with m/z values of 438 and 875, representing double charged and 
single charged HBAH, respectively. No peaks representing hydrogenobalamin 
(which has a mass of around 1270 Da) or any of the intermediates after HBAH (see 
Figure 3.1), could be detected in either sample, suggesting that the bacteria were 
unable to make any changes to HBAH. This indicates that there is a problem with 
the next step after HBAH, catalysed by CobC and CobD (see Figure 3.1). It is not 
clear whether these enzymes are inactive or whether the conditions were not 
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optimal for their activity. However, the real issue is likely to be a lack of CobD, since 
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Figure 3.9. Mass spectrometry trace from the E. coli ED661-cobCDPVU-
pET3a cell pellet and supernatant elution samples. A) Mass spectrum of the 
major peak from the cell pellet chromatogram. B) UV scan of the major peak from 
the cell pellet chromatogram. C) Mass spectrum of the major peak from the 
supernatant chromatogram. D) UV scan of the major peak from the supernatant 
chromatogram. HBAH double (438) and single charged (875) peaks were 
detected in both samples.   
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Due to the high HBAH-producing nature of the E. coli ED661 strain, it is possible 
that the bacteria were metabolically compromised and all of the required enzymes 
were not synthesised. The experiments were therefore repeated using E. coli 
BL21*(DE3) for protein expression. Since E. coli BL21*(DE3) is unable to make 
HBAH, the molecule was provided to the culture medium at a concentration of 10 
nM. In order for HBAH to be taken up by the cells, the outer membrane active 
transporter protein BtuB is required. However, E. coli BL21*(DE3) do not have a 
native functional BtuB. This is due to a nonsense mutation in the btuB gene (Studier 
et al, 2009), which causes translation to be terminated before the protein is fully 
synthesised. Therefore, to ensure maximum uptake of HBAH, a double 
transformation was carried out in which E. coli BL21*(DE3) was transformed with 
btuB-pLysS, a plasmid containing the btuB gene, and cobCDPVU-pET3a. Bacteria 
were then cultured, harvested and corrinoids purified from the bacterial cell pellet 
using a BtuF-bound nickel column and an RP18 column. The elution sample was 
analysed using HPLC-MS. 
 
Results showed that HBAH was indeed present, indicated by the 875 m/z peak, but 
with no signs of its modification since no larger peaks were seen (Figure 3.10) 
These results correspond with those seen previously, when using E. coli ED661, 
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Figure 3.10. Mass spectrometry trace from the E. coli BL21*(DE3)-btuB-
pLysS_cobCDPVU-pET3a cell pellet elution sample. A) UV chromatogram 
showing the different peaks coming off at different timepoints. B) UV scan of the 
major peak from the cell pellet chromatogram. C) Mass spectrum of the major 
peak (coming off at 14.7 minutes) from the cell pellet chromatogram. HBAH with 





Currently, very little is known about metal-free corrinoids in relation to both their 
structure and behaviour, in comparison to natural corrinoids. In 1965, metal-free 
corrinoids were first discovered and isolated from the photosynthetic bacterium A. 
vinosum (Toohey, 1965). Some of these metal-free corrinoids were investigated for 
potential activity as B12 inhibitors, including a neutral descobaltocobamide (I) and a 
positively charged descobaltocobinamide (II), whereby growth inhibition was seen in 
E. coli (Perlman and Toohey, 1966). Following on from this, a whole new class of 
metal-substituted B12 analogues, including those with copper, zinc or rhodium at 
their centre, were synthesised using the extracted metal-free corrinoids 
(Koppenhagen and Piffner,1970).  
 
The aim here was to investigate the possibility of engineering the production of B12 
variants, through the construction of an empty, metal-free B12 shell, and exploring 
what effect such compounds might have on cellular control elements, such as 
riboswitches. To construct this empty, metal-free B12 shell, a set of instructions that 
is able to be read and interpreted by E. coli was produced, in the form of a series of 
genes that are tied together into a single plasmid. Since no central metal ion was 
desired in this shell, the plasmid did not require the cobalt chelatase genes, 
cobNST, or the cobalt reductase, cobR. Additionally, the gene encoding the 
adenosyltransferase, CobO, was not required, because no upper ligand can be 
coordinated without a central metal ion. This meant that the plasmid was required to 
have the following genes, cobAIGJFMKLHB[QCDPVU]Alv, with the final six from A. 
vinosum. This is because the final six gene products are required to work on metal-
free intermediates.  
Unfortunately, despite the use of different cloning strategies and the use of various 
different competent cells, the desired plasmid containing the 
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cobAIGJFMKLHB[QCDPVU]Alv gene set, could not be constructed. This was most 
likely due to the plasmid being too large (over 20000 bp), making it toxic to the 
bacterial cells and reducing transformation efficiency. It was also thought that 
perhaps the plasmid had too many copies in the cell. Therefore, attempts were 
made to clone all of the genes into a more stable, low copy number plasmid, 
pETcocoR (Table 2.2). The majority of genes were successfully transferred to give 
cobAIGJFMKLHBQAlv-pETcocoR. The presence of the plasmid allowed bacteria to 
synthesise HBAH and therefore attempts were made to link the cob[CDPVU]Alv gene 
cluster to the genes in the new plasmid, cobAIGJFMKLHBQAlv-pETcocoR. 
Unfortunately, this was unsuccessful and a new approach was undertaken for the 
biosynthesis of hydrogenobalamin. 
 
This new approach involved transformation of E. coli ED661 (genetically engineered 
to contain cobAIGJFMKLH[BQ]Alv) with cobCDPVU-pET3a. However, following 
transformation, the strain was only able to synthesise HBAH and not 
hydrogenobinamide or hydrogenobalamin. Since it was thought that the cells may 
be metabolically compromised, resulting in limited expression of the cobCDPVU 
genes, experiments were repeated using E. coli BL21*(DE3) instead. HBAH was 
added externally this time. However, results were the same, showing no sign of 
hydrogenobalamin production or anything further than HBAH.  
 
Results indicated that there is a problem with the next step after HBAH, catalysed 
by CobC and CobD (Figure 3.1). It is not clear whether these enzymes are inactive 
or whether the conditions were not optimal for their activity. However, the real issue 
is likely to be a lack of CobD, since production of the protein could not be detected 
in previous experiments. The absence of CobC and CobD activity could also be due 
to a lack of protein a in E. coli, a protein thought to be required for CobC and CobD 
enzyme activity. In the aerobic pathway, CobC is supposedly part of a complex 
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called ‘protein b’ with the cobinamide synthase, CobD. Protein b (CobC and CobD 
complex) is thought to work together with another protein, protein a, to catalyse 
attachment of aminopropanol to adenosylcobyric acid in the presence of ATP and 
Mg2+ (Blanche et al, 1995), however, the exact identity or role of protein a is 
unknown. Together, CobC and CobD facilitate aminopropanol synthesis and 
attachment at C17 of adenosylcobyric acid (Warren et al, 2002; Cohen, 2014) in 
order to generate adenosylcobinamide (AdoCbi). In this case, A. vinosum CobC and 
CobD were expected to use HBAH as a substrate instead of adenosylcobyric acid, 
in order to generate hydrogenobinamide. However, this was not the case. Further 
analysis into CobD production would need to be carried out in order to find out the 
reason behind the lack of activity. One such method of further analysis could involve 
the codon optimisation of A. vinosum cobD, in order to increase the likelihood of 
CobD production. 
 
Since there appeared to be no sign of CobC or CobD activity, experiments were 
carried out to investigate the activity of CobP, CobV and CobU. These experiments 
are discussed in Chapter 4.  
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Chapter 4: Structure and 
activity analysis of the A. 





The final stages of B12 biosynthesis involve the assembly of the lower nucleotide 
loop, with the first step initiated by the bifunctional enzyme, CobP. CobP initiates 
the process of assembling the lower loop by converting AdoCbi into AdoCbi-GDP 
(Figure 4.1) (Warren et al, 2002) . CobP is a small, homodimeric protein with two 
different enzymatic functions, one as cobinamide kinase and the other as 
cobinamide phosphate guanylyltranserase. In the first step, CobP catalyses 
phosphorylation of the hydroxyl group of the aminopropanol in AdoCbi, using an 
ATP donor molecule, to form AdoCbi-phosphate (AdoCbi-P). In the second step, 
CobP transfers a GMP moiety, from a GTP donor, onto AdoCbi-P to form AdoCbi-
GDP (Blanche et al., 1991; Cohen, 2014).  
 
Finally, lower ligand synthesis and assembly requires two enzymes, CobU and 
CobV, to form AdoCbl from AdoCbi-GDP (Figure 4.1) (Warren et al, 2002). To begin 
with, CobU catalyses the formation of a glycosidic bond between b-nicotinate 
mononucleotide (NaMN) and DMB, in order to form α-ribazole phosphate (Blanche 
et al, 1991; Trzebiatowski et al, 1994; Mander and Liu, 2010). DMB, unless 
obtained from the environment, is synthesised from FMNH2 by an enzyme called 
BluB (an oxidoreductase that requires molecular oxygen) (Taga et al, 2007). The α-
ribazole phosphate is attached to AdoCbi-GDP by CobV, with the displacement of 

























































































































Figure 4.1. Enzymes involved in the conversion of adenosyl-cob(III)inamide 
to adenosylcob(III)alamin. This process requires the actions of three enzymes 
in the aerobic biosynthesis pathway; CobP, CobV and CobU. 
 
 
α -ribazole 5’ 
phosphate  
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In Chapter 3, it was observed that the cobCDPVU-3a plasmid was unable to provide 
bacteria with the ability to convert HBAH into hydrogenobalamin or even modify it 
slightly. However, evidence presented in Chapter 3 strongly indicates that the 
problem here lies with CobD, as it was not possible to detect any protein being 
produced. In contrast, both CobP and CobU appeared to be produced in 
comparatively large quantities. The aim of the research undertaken in this chapter 




4.2.1 Recombinant production and purification of CobP 
 
Previously in Chapter 3, A. vinosum CobP was successfully overproduced 
recombinantly in E. coli and purified. Results showed that the 22.5 kDa protein 
(which includes the 2.2 kDa N-terminal His-tag) was soluble and naturally found in 
the cytosolic region of the cell. However, upon further inspection, during which a 
smaller volume of eluted protein sample was loaded onto an SDS gel, CobP 
appeared to run as two protein bands instead of a single band as initially expected 
(Figure 4.2). 
 










From the data, it was not clear whether both bands represent the CobP protein, and 
if they do, whether one is a degraded form of the other. In order to confirm this was 
Figure 4.2. SDS-PAGE analysis of protein fractions collected during the 
purification of CobP from E. coli BL21*(DE3)-pLysS. CobP (22.5 kDa with His 
tag), is visible in the elutions. (Annotations: M – marker, T- total (resuspended 
sample), S – supernatant, P – pellet, FT –flow-through, BB – binding buffer, W1 – 






not just the result of an unwanted impurity, a fresh culture was prepared and CobP 
protein was purified in the same way. Again, two overproduced protein bands were 
seen. The most likely explanation for the presence of two protein bands is the 
degradation of CobP. This was investigated through the use of protease inhibitors. 
 
Due to the potential degradation seen with CobP, a frozen pellet of 1 L bacterial 
cells (prepared in the same way as before) was defrosted and protease inhibitor 
(10X SIGMAFAST protease inhibitor tablet dissolved in 10 mL double distilled 
water) was immediately added prior to sonication. CobP was then purified and 
fractions analysed using SDS-PAGE (Figure 4.3). Results showed two bands again, 
suggesting that the protein was still being degraded. 
 








Since this approach was unsuccessful, further procedures were tested. In the first, 
cells were cultured and grown fresh prior to the addition of protease inhibitor, as 
opposed to the addition of protease inhibitor to defrosted cells. In the second 
approach, cells were given a shorter induction time of 3 hours after the addition of 
Figure 4.3. SDS-PAGE analysis of fractions from the purification of CobP 
from E. coli BL21*(DE3)-pLysS in the presence of protease inhibitor complex. 
CobP (22.5 kDa) is visible in the elutions (soluble fractions. Two bands can be 





IPTG, as opposed to overnight incubation. Protein was then purified and fractions 
collected as previously described (Figure 4.4).  
 













From the SDS-PAGE analysis it was clear that the addition of protease inhibitor had 
no effect on the presence of two potential CobP bands, or the use of a shorter 
induction time. This could perhaps be due to the degradation occurring within the 
cells themselves, as opposed to during the purification of the protein, after cell lysis.  
 
In order to demonstrate that both bands are in fact representative of CobP, SDS-
PAGE was repeated and western blot analysis was performed using anti-His 
antibodies (capable of detecting the His-tag at the N-terminus of CobP). Samples 
from both the fresh purification, and the one with added protease inhibitors, were 
analysed (Figure 4.5). 
Figure 4.4. SDS-PAGE analysis of fractions from the purification of CobP 
from E. coli BL21*(DE3)-pLysS.  Two conditions: A) Purification following the 
addition of protease inhibitor to fresh cells. B) Purification following a short 3 h 




























Results from the western blot analysis suggest that both bands must represent 
CobP (with the N-terminal His-tag) as both cross-reacted with the anti-His 
antibodies.  Therefore, regardless of their exact size or sequence, both should 
contain at least the N-terminal region of the CobP protein, as this is where the His-
tag (6 Histidine residues) is located. The results suggest that the N-terminal is intact 
and there is degradation of the protein at the C-terminal region. It is highly unlikely 
that the shorter band is a result of the protein being made at a different start codon 
since this would results in only one band on the western blot. 
 
Figure 4.5. Analysis of the two protein bands for CobP purified with and 
without the addition of protease inhibitor (PI). Two methods of analysis: A.) 





As the degradation of CobP could not be prevented, an alternative route to 
obtaining pure, full-sized CobP protein was investigated. This involved producing 
CobP with a His-tag at the C-terminus instead of the N-terminus. If degradation is in 
fact occuring at the C-terminus, then only full sized CobP (with the C-terminal His-
tag) will bind the nickel column due to the cleaved fragment having lost its His-tag. 
A C-terminal His-tag can be incorporated by cloning the gene into a pET23b vector 
instead of a pET14b vector, and removing the natural STOP codon so that protein 
synthesis ends at the STOP codon found after the His-tag in pET23b.  
 
In order to clone cobP into pET23b, both a 5’ end NdeI restriction site and a 3’ end 
XhoI restriction site were required. To obtain these new sites, a reverse primer 
containing the XhoI restriction site was designed. The gene was then re-amplified, 
using PCR, from the A. vinosum genome. The amplified fragment was cloned into 
pET23b using the corresponding restriction sites within the plasmid and the new 
plasmid sequence was verified by sequencing. 
 
Once the cobP-pET23b plasmid was successfully constructed, it was used for the 
transformation of BL21*(DE3)-pLysS. Transformed bacterial cells were cultured, 
harvested and the purification of CobP was undertaken. Purification fractions were 
analysed using SDS-PAGE (Figure 4.6). 
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From the SDS-PAGE it appears there are still two bands for the CobP protein 
despite the change in location of the His-tag. Therefore, either there is no 
degradation at the C-terminus or the shorter, truncated protein is forming a complex 
with the full-sized protein which allows it to bind the nickel column and come 
through in the elutions. To differentiate between these possibilities, C-terminal His-
tagged CobP was analysed via western blotting (Figure 4.7). 
 
 
 M CobP (C-







Results from the western blot show the C-terminal His-tagged CobP sample to have 
only one band, suggesting that some form of degradation at the C-terminus has 
taken place.   
Figure 4.6. SDS-PAGE analysis of fractions from the purification of C-
terminal His-tagged CobP from E. coli BL21*(DE3)-pLysS. CobP protein is 




Figure 4.7 Western blot Analysis of CobP with a C-terminal His-tag. CobP 




4.2.2 Crystallisation of CobP  
 
Currently, there is no known crystal structure for CobP. A crystal structure would be 
beneficial in helping to understand how the protein works. Therefore, crystallisation 
was attempted in order to understand the mechanism of the enzyme, despite CobP 
purifying as two major forms.  
 
CobP was purified using IMAC and PD10 buffer exchange before being 
concentrated to a concentration of 15.6 mg/mL and further purified through a Fast 
Protein Liquid Chromatography (FPLC) machine that uses size exclusion 
chromatography to separate proteins. A G200 Increase column was first calibrated 
in PD10 buffer and proteins of known mass run through the column to create a 
standard curve for calibration, before running the protein of interest.  The FPLC 








Using the calibration curve, the protein mass was calculated to be 94 kDa. By 
dividing this value by the CobP monomer mass, 22.5 kDa, the number of monomers 
making up a molecule of the active protein could be determined. This was found to 
be approximately four, suggesting that CobP is running on the column as a 
tetramer. However, previous research from the literature has suggested CobP to be 
a homodimer (Blanche, Debussche et al. 1991). 
 
Fractions within and around the protein peak were run on an SDS gel to see which 
fractions had the most protein (Figure 4.9).  
 










The exact concentrations were verified using a nanodrop instrument. The most 
concentrated fraction (A9), with 9 mg/mL protein, was used to prepare four 24-well 
crystallisation trays, using conditions from structure screens 1 and 2 (Chapter 2, 
Section 2.4.21). 
 
No crystals were detected and therefore the process was repeated using the 
addition of substrate. Condition 8 of structure screen 2, (0.2 M ammonium 
phosphate monobasic, 0.1 M Tris pH 8.5 and 50% v/v 2-methyl-2,4-pentanediol 
(MPD)), was found to have a potential protein crystal, (Figure 4.10).  
Figure 4.9. SDS-PAGE analysis of CobP (22.5 kDa) purified sample and 
fractions A7-A10 from within the FPLC protein peak region. The majority of 







The crystal, however, dissolved before it could be analysed further. The condition 
was therefore optimised (Chapter 2, Section 2.4.22, Table 2.13). Other promising 
conditions were also repeated simultaneously; 12, 13 and 44 of screen 1, along with 
3, 19, 25, 42 and 43 of screen 2. Needles were observed in condition 25 of structure 
screen 2 (0.01 M cobalt (II) chloride hexahydrate, 1.8 M (NH4)2SO4 pH 6.5, 0.1 M 




Attempts were made to optimise the condition that had resulted in needle formation 
(Chapter 2, Section 2.4.22, Table 2.14). Trays were set up using a higher CobP 
concentration of 0.5 mM.  
 
Figure 4.10. Potential CobP crystal. Condition 8 of molecular dimensions SS2 
(0.2 M ammonium phosphate monobasic, 0.1 M Tris pH 8.5 and 50% v/v MPD). 
 
 
Figure 4.11. CobP needles. Detected in condition 25 of molecular dimensions 




New trays were also prepared for the 100 conditions from structure screens 1 and 
2, using 0.7 mM CobP. Small crystals were observed in condition 8 (structure 
screen 2), as well as a larger crystal in an optimised condition (0.2 M ammonium 




The condition producing a large CobP crystal was optimised further (Chapter 2, 
Section 2.4.22, Table 2.15). Crystals were observed in two of these newly optimised 








Figure 4.12. Large CobP crystal. Detected in optimised condition containing: 
0.2 M ammonium phosphate monobasic, 0.1 M Tris, pH 7.5, 40% v/v MPD. 
 
 
Figure 4.13. Potential CobP crystals. A.) Two identical shaped crystals in the 
condition containing; 0.1 M Tris pH 8.5, 50% v/v MPD, 0.2 M ammonium 
phosphate B.) Coloured microcrystals in the condition containing: 1 M Tris, pH 




The larger crystal (Figure 4.13A) was analysed by X-ray diffraction, with results 
demonstrating the crystal to be salt instead of protein. The coloured nature of the 
second set of crystals, suggested protein had bound to the coloured Cbi substrate 
and crystallised. Alternatively, it could be that the Cbi had crystallised on its own. 
Unfortunately, the crystals dissolved before they could be analysed further.   
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4.2.3 Crystallisation of CobU protein 
 
Currently there are a number of structures solved for the anaerobic version of the 
CobU enzyme, known as CobT. However, there are no structures for the B12 
biosynthesis enzymes found in A. vinosum bacteria. Since this strain of bacteria has 
been reported to produce metal-free B12 analogues, it is of great interest to see how 
the enzymes from A. vinosum compare to those that are unable to produce metal-
free B12 analogues. Therefore, crystallisation of A. vinosum CobU was attempted.  
 
CobU was purified using IMAC and PD10 buffer exchange before being 
concentrated to a concentration of 2 mg/mL and further purified through an FPLC 





The concentration of eluted protein was calculated using an A280 reading and the 



















verified using a nanodrop. The eluted protein was used to prepare four 24-well 
crystallisation trays, using conditions from structure screens 1 and 2 (Chapter 2, 
Section 2.4.21). 
 
Small crystals were observed in conditions 14 (0.2 M (NH4)2SO4, 30% w/v 
polyethylene glycol (PEG) 8000, 0.1 M sodium cacodylate pH 6.5), 15 (0.2 M 
magnesium acetate tetrahydrate, 20% w/v PEG 8000, 0.1 M sodium cacodylate pH 
6.5) and 30 (2.0 M (NH4)2SO4, 2% V/v PEG 400, 0.1 M sodium 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) pH 7.5) of structure screen 1. 
Optimisation screens were prepared for each condition, in order to produce larger, 
more well-defined crystals (Chapter 2, Section 2.4.22; Tables 2.16, 2.17 and 2.18). 
Two conditions (0.1 M sodium cacodylate (Na/Caco), 0.15 M (NH4)2SO4, 20% PEG 
and 0.1 M Na/Caco, 0.1 M magnesium acetate (Mg/Ace), 15%) grew distinct 
crystals (Figure 4.15) which were picked for X-ray diffraction (Chapter 2, Section 
2.4.23). 
 




Figure 4.15. CobU crystals. Detected in the following conditions: A) 0.1 M 
Na/Caco, 0.15 M (NH4)2SO4, 20% PEG from SS1 condition 14 screen, B) 0.1 M 
Na/Caco, 0.1 M Mg/Ace, 15% PEG from SS1 condition 15 screen. 
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Both samples were found to contain protein crystals and diffraction data were 
obtained for each. However, due to anisotropy and the formation of ice rings, a 
structure for CobU could not be generated.  
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4.2.4 The synthesis of adenosylcobinamide to investigate the 
activity of CobP 
 
In order to determine if CobP is active, substrate for the enzyme needs to be 
prepared, specifically the synthesis of AdoCbi. This section describes the use of 
BtuR to produce AdoCbi from Cbi, following the decyanation of CNCbi into Cbi, for 
subsequent use in CobP activity assays. One way of synthesising the CobP 
substrate, AdoCbi, involves the use of the BtuR enzyme, which is the 
adenosyltransferase found in E. coli that has the ability to adenosylate Cbi into 
AdoCbi (Lundrigan et al, 1991), Figure 4.16. BtuR was overexpressed by culturing 
BL21*(DE3)-pLysS-btuR-pET14b (provided by Dr. Evelyne Deery), and purified 
















































Figure 4.16. The conversion of cobinamide to adenosylcobinamide by 
BtuR. BtuR, an adenosyltransferase, catalyses the conversion of cobinamide 
into adenosylcobinamide.  
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The first stage involved the decyanation of CNCbi (obtained from Sigma) into Cbi, 
via a number of chemical reactions, under anaerobic conditions. This involved the 
reduction of Co3+ in CNCbi to Co1+ using sodium borohydride. Incubation with 
sodium borohydride was carried out for 2-3 hours, by which point completion of the 
reaction could be detected by a colour change from red/purple to grey/purple. Sep 
Pak Plus C18 RP18 cartridges were set up and activated with 30 mL methanol 
before equilibration with 10 mL de-gassed H2O. The reduced Cbi was then passed 
through the column and eluted with 5 mL methanol before drying down in a vacuum 
centrifuge. 
 
In the second stage, the adenosyl upper ligand was attached to Cbi through the 
action of BtuR, in order to produce AdoCbi. Purified BtuR protein was taken into a 
glove box and run through a PD10 column anaerobically so that an absorbance 
scan measurement could be taken. This was used to calculate the concentration of 
BtuR. Similarly, the concentration of Cbi was calculated after dissolving the dried 
powder in PD10 buffer. The assay (set up as described in Chapter 2, Section 
2.3.17) was carried out in the dark due to the light sensitivity of AdoCbi, and to 
prevent removal of the adenosyl group, before incubating overnight in the glove 
box. 
 
Once incubation was complete, the solution was centrifuged for 15 minutes at 4000 
rpm in order to deposit the protein to the bottom of the tube. The supernatant was 
run through an RP18 column and AdoCbi eluted in 50% ethanol (Chapter 2, Section 
2.4.18). A 50 µL sample was also removed for analysis using HPLC-MS (Chapter 2, 
Sections 2.4.19 and 2.4.20) to confirm that the sample was indeed AdoCbi. Results 
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Figure 4.17. Mass spectrometry results showing the production of AdoCbi. 
A.) UV chromatogram showing the different peaks coming off at different 
timepoints. B.) Mass spectrometry trace of the large peak seen in (A) coming off 
at 17.6 minutes. The 1239.58 peak represents the mass for AdoCbi, suggesting 




4.2.5 In vivo CobP activity assays 
 
In Chapter 3, it was seen that the enzymes encoded by the cobCDPVU-pET3a 
plasmid had no effect on HBAH as they would be expected to. Therefore, to see if 
any CobP, CobV or CobU activity could be detected, the same growth experiments 
were carried out using a later intermediate in the pathway, Cbi (the substrate for 
CobP).  
 
E. coli BL21*(DE3)-pLysS-cobCDPVU-pET3a was grown with the addition of 100 
pM CNCbi, and samples prepared as described in Chapter 2, Section 2.3.18. 
Corrinoids were purified using a BtuF-bound nickel column and a RP18 column. 
Elutions from the supernatant and pellet samples were analysed using HPLC-MS. 
The results indicated no production of Cbl or any CobP enzyme products (Cbi-GDP 
or Cbi-P) with only the starting material, CNCbi, detected. 
 
Next, E. coli BL21*(DE3)-pLysS-cobCDPVU-pET3a and E. coli BL21*(DE3)-pLysS 
were individually grown, with the addition of 80 nM newly synthesised AdoCbi. In 
the control culture, lacking any A. vinosum enzymes, no molecules could be 
detected with masses that correspond to Ado-Cbi-P, Ado-Cbi-GDP or AdoCbl. In 
the culture containing cobCDPVU-pET3a, AdoCbi appears to have been modified to 
a molecule with a mass unit value of 1557.63 Da, ~22 Da less than that of AdoCbl 
and ~318 Da greater than AdoCbi (Figure 4.18). This was not detected in the 






In order to confirm whether the adenosyl group was still attached in the molecule of 
1557.63 Da mass, the sample had cyanide added (to displace any adenosyl at the 
upper ligand position) before analysing again. Results show a peak of smaller mass 
suggesting that the adenosyl group was successfully replaced with the cyano-group 
(Figure 4.19). The most likely suggestion for this is the addition of a lower ligand 
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Figure 4.18. Mass spectrometry results showing the production of an 
unrecognisable molecule from AdoCbi. A.) UV chromatogram. B.) Mass 
spectrometry trace showing the 1557.63 peak representing a molecule 






Although the structure of the compound remains unknown, the fact that this was not 
seen in the control experiment suggests that the A. vinosum enzymes had some 
role in its production. A more in-depth MS-MS and NMR study would be needed to 
identify the lower ligand that was being attached. Due to this ambiguity of results 
when working in vivo, attempts were made at an in vitro approach using purified A. 
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Figure 4.19. Mass spectrometry results showing the change in the assay 
product following cyanide addition. A.) UV trace of the 1333.55 mass unit 
molecule. B.) Mass spectrometry trace showing the 1333.55 peak. 
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4.2.6 In vitro CobP activity assays  
 
In order to detect A. vinosum CobP enzyme activity, an in vitro approach using 
purified enzyme, various different Cbi substrates, and additional cofactors (MgCl2 
and GTP/ATP) was trialled. These experiments are described in Chapter 2, Section 
2.4.25.  
 
Initially, 0.6 µM of purified CobP was used in the assays (Table 2.19) and tested 
alongside controls lacking protein and controls lacking GTP/ATP. Results showed 
no difference in the assays that did or did not have protein (Figure 4.20). Therefore, 
a higher concentration of protein, 6 µM, was used and a different buffer pH also 
tested. Each reaction was carried out with 20 µM of each Cbi at both the original pH 
of 8 and a new higher pH of 9, to see if conditions could be optimised (Table 2.20). 
Results showed a peak for AdoCbi-P in the sample provided with AdoCbi, in pH 9 
buffer. This suggested that the enzyme is active and a pH of 9 is more optimal for 
the enzyme (Figure 4.21). Previously carried out research also suggests an optimal 
pH of around 9 (Blanche et al, 1991). Additionally, AdoCbi was seen to be the 
optimal substrate as opposed to OHCbi, and therefore only AdoCbi was used for 











Figure 4.20. Mass Spectrometry traces from CobP activity assays. Assays 1-4 
were controls containing no CobP protein, in which no activity should be detected. 
Assays 5-6 were no ATP/GTP controls, in which no activity should be detected. 
Assays 7-10 all contain CobP, either ATP or GTP (to determine which works better 
in this assay) and either OHCbi or AdoCbi as the substrate. The exact components 
in each assay are outlined as follows: 1.) GTP, AdoCbi. 2.) GTP, OHCbi. 3.) ATP, 
AdoCbi. 4.) ATP, OHCbi. 5.) CobP, AdoCbi. 6.) CobP, OHCbi. 7.) CobP, AdoCbi, 
GTP. 8.) CobP, Cbi, GTP. 9.) CobP, AdoCbi, ATP. 10.) CobP, Cbi, ATP. In all ten 
assays, no changes were seen to be made to either AdoCbi or OHCbi, therefore 















Figure 4.21. Mass spectrometry traces from CobP activity assays in 
optimised buffer conditions. Assay carried out at pH 8 (above) shows only 
background peaks and no indication of AdoCbi-P presence. Assay carried out at 
pH 9 (below) shows a peak with a mass corresponding to that of AdoCbi-P 




Following the initial detection of CobP activity, an even higher concentration of 
CobP (60 µM) was investigated for improved assay performance (Table 2.21). 
Reactions were tested in both the presence and absence of DTT (Table 2.21). This 
is because DTT prevents cysteine oxidation (Yang et al, 2012), and cysteine 
oxidation within the active site could potentially be a factor hindering CobP activity. 
Additionally, control reactions were carried out using lysate from cultures 
overproducing A. vinosum CobP, lysate from cultures overproducing R. capsulatus 
CobP and purified R. capsulatus CobP, in addition to the standard reaction using 
only purified A. vinosum CobP.  
 
Results showed that the presence of DTT had no effect on CobP activity (Figure 
4.22A and 4.22B), suggesting that cysteine oxidation at the CobP active site was 
not hindering its activity. A. vinosum CobP was found to be active, since purified 
protein generated the desired product, Ado-GDP-Cbi. This signal was stronger 
when lysate from the same culture was used instead of purified protein directly 
(Figure 4.22A and 4.22C), suggesting that perhaps there may be a component 
present in the lysate that is required for optimal CobP activity. This could potentially 
be a cofactor or metal ion. R. capsulatus CobP was found to be more active than A. 
vinosum CobP since the Ado-GDP-Cbi signal was stronger than that generated by 
A. vinosum CobP (Figure 4.22A and 4.22D). However, without quantifying the 
substrate to product turnover, it cannot be said how much more active the R. 









1_26_01_6877.d: EIC 832.8000±0.2 +All MS
4_29_01_6880.d: EIC 832.8000±0.2 +All MS
7_32_01_6883.d: EIC 832.8000±0.2 +All MS
8_33_01_6884.d: EIC (720.7600; 707.7500)±0.2 +All MS
10_35_01_6886.d: EIC 832.8000±0.2 +All MS
11_36_01_6887.d: EIC (720.7600; 707.7500)±0.2 +All MS
17_42_01_6893.d: EIC (707.7500; 720.7600)±0.2 +
13_38_01_6889.d: EIC 832.8000±0.2 +All MS






























































0 10 20 30 40 50 Time [min]
1_26_01_6877.d: EIC 832.8000±0.2 +All MS
4_29_01_6880.d: EIC 832.8000±0.2 +All MS
7_32_01_6883.d: EIC 832.8000±0.2 +All MS
8_33_01_6884.d: EIC (720.7600; 707.7500)±0.2 +All MS
10_35_01_6886.d: EIC 832.8000±0.2 +All MS
11_36_01_6887.d: EIC (720.7600; 707.7500)±0.2 +All MS
17_42_01_6893.d: EIC (707.7500; 720.7600)±0.2 +
13_38_01_6889.d: EIC 832.8000±0.2 +All MS






























































0 10 20 30 40 50 Time [min]
1_26_01_6877.d: EIC 832.8000±0.2 +All MS
4_29_01_6880.d: EIC 832.8000±0.2 +All MS
7_32_01_6883.d: EIC 832.8000±0.2 +All MS
8_33_01_6884.d: EIC (720.7600; 707.7500)±0.2 +All MS
10_35_01_6886.d: EIC 832.8000±0.2 +All MS
11_36_01_6887.d: EIC (720.7600; 707.7500)±0.2 +All MS
17_42_01_6893.d: EIC (707.7500; 720.7600)±0.2 +
13_38_01_6889.d: EIC 832.8000±0.2 +All MS






























































0 10 20 30 40 50 Time [min]
1_26_01_6877.d: EIC 832.8000±0.2 +All MS
4_29_01_6880.d: EIC 832.8000±0.2 +All MS
7_32_01_6883.d: EIC 832.8000±0.2 +All MS
8_33_01_6884.d: EIC (720.7600; 707.7500)±0.2 +All MS
10_35_01_6886.d: EIC 832.8000±0.2 +All MS
11_36_01_6887.d: EIC (720.7600; 707.7500)±0.2 +All MS
17_42_01_6893.d: EIC (707.7500; 720.7600)±0.2 +
13_38_01_6889.d: EIC 832.8000±0.2 +All MS






























































0 10 20 30 40 50 Time [min]
1_26_01_6877.d: EIC 832.8000±0.2 +All MS
4_29_01_6880.d: EIC 832.8000±0.2 +All MS
7_32_01_6883.d: EIC 832.8000±0.2 +All MS
8_33_01_6884.d: EIC (720.7600; 707.7500)±0.2 +All MS
10_35_01_6886.d: EIC 832.8000±0.2 +All MS
11_36_01_6887.d: EIC (720.7600; 707.7500)±0.2 +All MS
17_42_01_6893.d: EIC (707.7500; 720.7600)±0.2 +
13_38_01_6889.d: EIC 832.8000±0.2 +All MS
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Figure 4.22. Mass spectrometry results for the production of AdoCbi-GDP 
from AdoCbi. A) Assay using purified A. vinosum CobP, B) Assay using purified 
A. vinosum CobP in the presence of 10 mM DTT, C) Assay using lysate from A. 
vi osum CobP overproducing culture, D) Assay using purified R. capsulatus 




In a final assay set, the lysate overproducing A. vinosum CobP was compared to 
that of standard BL21*(DE3)-pET14b, in order to confirm that the activity was 
indeed coming from the A. vinosum CobP and not solely from something found in 
the lysate. Purified A. vinosum CobP at a 10X higher concentration of 600 µM was 
also tested in the presence and absence of standard BL21*(DE3)-pET14b lysate 
(Table 2.22). Additionally, a final control containing no lysate and no purified protein 
was also prepared. Of the five reactions, the A. vinosum CobP overproducing lysate 
was seen to generate the most Ado-GDP-Cbi, with the greatest turnover of 
substrate to product (Figure 4.23), demonstrating that BL21*(DE3)-pET14b lysate 
alone has some background activity, but since the substrate to product turnover 
seen in the A. vinosum CobP overproducing lysate is over 4 times greater, the 
CobP enzyme must be responsible for this greater activity. In the BL21*(DE3)-
pET14b lysate samples, turnover was 1-2%, regardless of the presence of purified 
CobP protein. This final set of results shows that while A. vinosum CobP does have 
activity, this activity is very low and there must be some underlying problem causing 
this, such as the substrate not being optimal for the enzyme. Additionally, the 
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Figure 4.23. Graph to show the rate of AdoCbi turnover, to form AdoCbi-






The work carried out in this chapter is heavily focused on working out the structure 
of two B12 biosynthesis enzymes from A. vinosum, CobP and CobU, and 
determining whether the recombinantly produced proteins are active and suitable 
for the ‘ex vivo’ synthesis of corrins. Currently, very little is known in the literature 
about the structure of CobP due to the lack of a crystal structure. The structure of 
CobU, from the aerobic pathway, has not yet been solved either. However, the 
anaerobic version of the enzyme, known as CobT, has had its structure solved. For 
example, CobT from Salmonella enterica has a crystal structure which shows the 
enzyme to be a dimer, with each subunit consisting of two domains (Cheong et al, 
1999). Similarly, CobP is also thought to be a homodimer due to previous research 
carried out where the protein was found to have double the molecular weight on 
native-PAGE compared to when denatured on SDS-PAGE (Blanche et al, 1991). 
 
In terms of its function as an enzyme, CobP is thought to be a bifunctional protein 
with the ability to act both as a cobinamide kinase and cobinamide phosphate 
guanylyltransferase (Blanche et al, 1991). This putative bifunctional nature of CobP 
opens up an interesting question in relation to its structure and whether the two 
reactions that are carried out occur at the same active site or at different sites, 
whereby an intermediate is transferred between them. Additionally, the A. vinosum 
enzymes are interesting in general, due to the bacterium’s ability to synthesise 
metal-free corrinoids (as discussed in Chapter 3). 
 
Unfortunately, despite many attempts, crystallisation of CobP proved unsuccessful. 
Initial experiments on the protein determined that CobP was subject to some form of 
C-terminal cleavage. It is perhaps for this reason that the protein could not be 
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crystallised, since crystallisation requires homogenous solutions with all protein 
components being identical, allowing them to form identical, tightly packed lattices.  
 
In contrast, CobU crystallised much more readily, producing a range of crystal 
shapes depending on the condition of growth. Unfortunately, due to problems during 
the freezing of crystals, difficulties arose during X-ray diffraction which prohibited 
the collection of appropriate structural data. One crystal provided a diffraction data 
set that was Space Group P21 and which diffracted with an average overall 
resolution of 2.7Å. However, as the data were anisotropic, it was not possible to 
generate a structure using molecular replacement with the structural information 
from the S. enterica CobT crystal structure (Cheong et al, 1999). Future work would 
require further refining of the crystal-producing conditions, followed by improved 
cryo-protectants such that there is no anisotropy or formation of ice rings. 
 
Subsequent to the structural analysis work carried out on CobP and CobU, the 
activity of CobP was investigated, following on from in vivo growth assays carried 
out in Chapter 3, where all five genes in the cobCDPVU-3a plasmid were trialled 
together. Here the focus was more specifically on the activity of CobP. Initial in vivo 
experiments showed some form of modification to the AdoCbi substrate, which 
suggested that A. vinosum CobP may be active (since the same result did not occur 
in the control lacking the cobCDPVU-3a plasmid). Additionally, CobV appeared to 
incorporate some form of lower ligand to the cobalt ion, suggesting that CobV is 
also being recombinantly produced. However, the resulting product could not be 
deduced, as the attached lower ligand was not of a size that was recognised.  
 
In order to investigate CobP activity further, in vitro activity assays were carried out. 
Results showed that optimal activity was observed when taking protein along with 
the lysate from which it originates, suggesting that there may be an unknown 
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component in the lysate aiding the reaction. Alternatively, it may be that the correct 




Chapter 5: An in vitro 
characterisation of the E. 





This study focuses on the control of the btuB riboswitch, and in turn B12 uptake, via 
the btuB gene product, BtuB. Riboswitches are short mRNA sequences that are 
bound by a ligand/metabolite to terminate transcription/translation of the associated 
gene(s). One of the first discovered riboswitches was the B12 riboswitch. When B12 
is bound to this mRNA sequence, expression of B12-related genes is switched off. 
These riboswitches are discussed in more detail in Chapter 1, where structures of 
B12 riboswitches are also shown. 
 
Initial work on the btuB riboswitch began when the level of btuB expression within E. 
coli was found to be controlled by an mRNA leader sequence (Lundrigan et al, 
1991). This mRNA leader sequence was later discovered to be an AdoCbl-
responsive riboswitch, the btuB riboswitch, controlling btuB gene expression in 
response to AdoCbl binding. AdoCbl was found to bind directly to the mRNA and 
induce a structural reorganisation, which results in a change in expression levels 
(Nahvi et al, 2002). Through the use of primer extension-inhibition assays, which 
measure the ability of bound ribosomes to block extension by reverse transcriptase 
of a primer hybridized to the btuB RNA, the concentration of AdoCbl required to 
cause half-maximal inhibition has been estimated to be 0.3 µM (Nou and Kadner, 
2000). Following this, in-line probing studies were carried out which yielded 
apparent KD values of 0.3 µM for AdoCbl binding to the btuB riboswitch (Nahvi et al, 
2002). Thus, a concentration of 0.3 µM of ligand is required to alter the structure of 
half of the RNA molecules present. 
 
The following investigations were aimed at determining the effectiveness of the E. 
coli btuB riboswitch using an in vitro transcription/translation kit, a method allowing 
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changes in levels of the gene product to be established in response to increasing 
B12 concentrations. This approach has the potential to allow a more accurate and 
direct determination of the riboswitch response to B12 concentrations and examine 
the ability of the riboswitch to respond to B12 variants. In order to gain greater insight 
into aspects of molecular recognition, various B12 analogues were investigated for 
their ability to bind and structurally alter the btuB riboswitch.  
 
The natural variants investigated in this chapter include AdoCbl, CNCbl, AdoCbi 
and CNCbi, all of which are compounds with either a 5’-deoxyadenosyl or cyano 
group upper ligand. The remaining unnatural variants were synthesised by Dr. 
Florian Widner and Christoph Kieninger, and provided by Professor Bernhard 
Kräutler at the University of Innsbruck. The first of these is the unnatural AdoCbl 
analogue, adenosylrhodibalamin (AdoRbl), which differs to AdoCbl only in the 
nature of the central metal ion where cobalt is replaced with rhodium (Widner et al, 
2016). The next two variants differ to AdoCbl in their upper ligand where the 5’-
deoxyadenosyl group is replaced with difluorophenylethinyl and ethylphenyl upper 
ligands in order to produce difluorophenylethinylcobalamin (F2PhEtyCbl) and 
ethylphenylcobalamin (EtPhCbl), respectively (Ruetz and Salchner et al, 2013; 
Ruetz and Gherasim et al, 2013). The final variants consist of altered central metal 
ions where cobalt is replaced with zinc and nickel to produce zincobalamin (Znbl) 
and nibalamin (Nibl), respectively. Due to a different coordination chemistry to both 
cobalt and rhodium, neither zinc nor nickel are able to coordinate upper ligands and 
therefore Znbl and Nibl lack an upper ligand completely. They do however contain 
DMB at the lower ligand position. The various combinations of ligands and the 







In this study, three key areas of B12 are investigated for their importance in 
riboswitch recognition, the central metal ion, the upper ligand and the lower ligand. 
Firstly, the central metal ion, which coordinates the upper and lower ligand, was 
studied. This was done through the use of various different unnatural B12 variants, 
whose antivitamin potentials (whether they bind the same sites as B12, but without 
carrying out the same function) were also looked into. These include antivitamins 













































Figure 5.1 General structure of B12 alongside the different upper ligand 
variations found in variants of the molecule. DMB (the lower ligand, shown 
inside red circle) is not present in the cobinamides (AdoCbi and CNCbi). X (upper 
ligand) = 5’deoxyadenosyl (AdoCbl, AdoRbl, AdoCbi), CN (CNCbl, CNCbi), 
ethylphenyl (EtPhCbl), diflurophenylethinyl (F2PhEtyCbl). M (central metal ion) = 
cobalt (AdoCbl, CNCbl, AdoCbi, CNCbi, EtPhCbl, F2PhEtyCbl), rhodium 
(AdoRbl), zinc (Znbl), nickel (Nibl). 
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ion found naturally in B12. The second aspect that was looked into was the upper 
ligand itself. The current research shows a preference for the adenosyl group at the 
upper ligand position (Nahvi et al, 2002; Gallo et al, 2008). Various upper ligands 
are tested here (Figure 5.1). Finally, the importance of the lower ligand and the B12 
base on/ base off coordination was investigated.  
 
Another aim was to develop a switch with the ability to sense B12 levels, linked to a 
fluorescent reporter. This was done using synthetic biology techniques, using an 
approach similar to that recently reported by Cai et al, (Cai et al, 2018). If 
successful, such a switch could be used in various different biological systems to 
determine a correlation between B12 concentrations and the concentration of a 
reporter gene. Furthermore, the system can then be trialled in high B12-producing 
bacterial strains to compare B12 production levels.  
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5.2 Results 
5.2.1 Preparation of a riboswitch-controlled reporter gene 
construct, ‘Rib70_eGFP_pET14b’ 
 
A number of studies on the btuB riboswitch have all found that the putative 240 bp 
btuB riboswitch (Figure 5.2) on its own is not enough to control the expression of a 
reporter gene, suggesting that the riboswitch is non-functional without the beginning 
of the btuB coding region (Franklund and Kadner, 1997; Nou and Kadner, 2000; 
Lundrigan et al, 1991). These studies show that a large fragment from the coding 








Figure 5.2. The E. coli btuB riboswitch sequence. Image adapted from Gallo et 
al, 2008. Cleavage sites, in the absence of AdoCbl, are indicated by red triangles 
(1-8).  
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Initially, the btuB riboswitch containing the first 70 codons of the btuB gene was 
amplified from the E. coli BL21*(DE3) genome. However, upon closer analysis, it 
appeared that the BL21*(DE3) genome has a natural, in frame, stop codon (TAG), 
within the first 70 codons of btuB (Marisch et al, 2013) due to a C to T mutation at 
the +38 position. Therefore, E. coli K12 MG1655 genomic DNA (without the 
mutation in the btuB gene) was used instead. 
 
PCR was carried out (Chapter 2, Section 2.3.7), using the Rib_For and Rib70_Rev 
primers (Table 2.3). The PCR-amplified sample was run on a 1% agarose gel, the 
appropriate ~ 460 bp band was extracted and the DNA was purified from the 
agarose (Chapter 2, Section 2.3.10), before digesting with XbaI/NdeI restriction 
enzymes. The use of these particular restriction enzymes allows the fragment to be 
cloned downstream of the T7 promoter in the pET14b vector, before the start codon 
of the eGFP reporter gene. Therefore, this combination of sites allows the 
riboswitch to sit correctly in frame between the T7 promoter and the eGFP reporter 
gene. A ligation between the XbaI/NdeI digested riboswitch (insert) and XbaI/NdeI 
digested eGFP-pET14b (vector) DNA was performed. The resultant plasmid (Figure 







Overnight LB starter cultures were prepared from the transformed cells. After 
overnight growth the starter cultures were centrifuged and plasmid DNA was 
extracted. Samples were sent off to GeneWiz for sequencing, which verified that the 
riboswitch had been amplified correctly and the Rib70_eGFP_pET14b plasmid 
sequence is as expected.  
 
In order to check whether Rib70_eGFP_pET14b would allow production of eGFP, 
the plasmid was used for the transformation of BL21*(DE3)-pLysS and 
transformants were cultured in M9 minimal medium. The pellets from the test 
cultures were found to be green, indicating that eGFP was being produced 
successfully.  
Figure 5.3. Cloning strategy for the construction of the Rib70_eGFP_pET14b 
plasmid. Insertion of the amplified riboswitch fragment (Riboswitch + btuB70) into 
eGFP-pET14b was carried out using XbaI and NdeI restriction sites. 
Rib70_eGFP_pET14b contains Riboswitch-btuB70 upstream of the eGFP 
reporter gene under the control of a T7 promoter and terminator. The plasmid also 
contains an ampicillin resistance gene, AmpR and its promoter, AmpR promoter, 
for selection purposes. 
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5.2.2 Investigation of riboswitch-controlled eGFP expression, 
in the presence of AdoCbl, using in vitro protein synthesis 
experiments 
In order to investigate the control and activity of the riboswitch, in response to 
increasing concentrations of AdoCbl, in vitro protein synthesis experiments were 
carried out using the NEB PURExpress in vitro protein synthesis kit. PURExpress is 
a cell-free transcription/translation system that is reconstituted from the purified 
components that are necessary for E. coli gene expression. Transcription and 
translation are carried out in a one-step reaction, and require the mixing of only two 




Initially, only AdoCbl (obtained from Sigma-Aldrich) was investigated at three 
different concentrations using the in vitro system, (Chapter 2, Section 2.3.15), as a 
proof of principle to show that the effect of B12 on riboswitch-controlled eGFP gene 
expression can be investigated in this manner. Resultant protein production was 
analysed using SDS-PAGE (Figure 5.5). 
Figure 5.4. Diagram representing the PURExpress one-step reaction 
required for transcription/translation. Tubes A and B contain the components 


















The eGFP protein (28.9 kDa with the His-tag) appears to be present in the eGFP-
pET14b control (lane 2). This was expected, as this plasmid is the only one capable 
of making His-tagged eGFP of this size. Lane 3 appears to have an extra band 
sized around 36 kDa (indicated by the purple arrow). This is the BtuB-eGFP hybrid, 
consisting of the first 70 amino acids of BtuB attached to eGFP. Its absence in lanes 
4-6 shows that the added AdoCbl is behind this reduced protein production. This 
demonstrates that AdoCbl is successfully switching off the riboswitch in the Rib70-
eGFP-pET14b plasmid. 
 
In order to verify that the suspected eGFP bands were in fact eGFP, a western blot 
was carried out using anti-eGFP antibodies (Figure 5.6). 
Figure 5.5. SDS-PAGE analysis of in vitro reaction samples. All reaction 
samples were run on a 12.5% SDS gel in order to compare protein bands in each 
sample. Lanes 1-6 contain different plasmids and plasmid conditions: 1.) pET14b 
2.) eGFP-pET14b 3.) Rib70_eGFP_pET14b 4.) Rib70_eGFP_pET14b + 10 µM 
AdoCbl 5.) Rib70_eGFP_pET14b + 25 µM AdoCbl 6.) Rib70_eGFP_pET14b + 50 
µM AdoCbl. Alongside all the transcription/translation components, two additional 
proteins can be seen. These are the 28.9 kDa eGFP protein (circled in red) and 
the 36.2 kDa eGFP fusion protein containing the first 70 codons of btuB (indicated 
by the purple arrow). 
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The western blot confirms that the riboswitch encoded within the Rib70-eGFP-
pET14b plasmid is switched off in the presence of AdoCbl, as expected, and that 
the decrease in production of eGFP is related to the concentration of AdoCbl within 
the reaction mix. 
 
In order to get an estimate of the levels of eGFP being produced in each reaction, 
the western blot procedure was repeated with the reactions run alongside a set of 
eGFP standards of known concentration. eGFP standards, from 0 to 4 µM, were 
used to generate a standard curve for estimating relative eGFP levels in each of the 
in vitro reaction samples, (Figure 5.7). This was carried out each time a set of 
reactions was run on a western blot. 
  
Figure 5.6. Western blot analysis showing the effect of AdoCbl on the E. 
coli btuB riboswitch. Bands represent the eGFP present in the in vitro protein 
synthesis reactions, using the Rib70_eGFP_pET14b plasmid in the presence of 
increasing concentrations of AdoCbl. Decreased levels of eGFP can be seen as 
AdoCbl concentration is increased from 0 to 50 µM. 
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Densitometry analysis was carried out on the blot using ImageJ software. The 
density of the four visible eGFP standard bands was used to prepare a calibration 





















Figure 5.7. Western blot showing eGFP standards of known concentration. 
Four different concentrations of eGFP were run: 4 µM, 2 µM, 1 µM and 0.5 µM.   
Figure 5.8. eGFP calibration curve. Four different concentrations of eGFP (4 
µM, 2 µM, 1 µM and 0.5 µM) were analysed on a western blot and densitometry 
was carried out for each of the bands, using ImageJ. The densitometry values 
were used to generate a calibration curve. 
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Using the equation from the calibration curve, relative eGFP concentrations could 
be calculated for the relative density values from each of the reaction sample 
bands. The densitometry results allow a much clearer distinction between the eGFP 
in the samples, as opposed to comparing band intensity by eye.  
 
Following the initial proof of principle experiments, the effect of AdoCbl on the 
riboswitch was investigated over a wider concentration range and experiments were 
carried out in duplicate or triplicate. eGFP concentrations were not only analysed by 
densitometry but also by measuring fluorescence intensity. However, fluorescence 
analysis was possible only with certain variants due to fluorescence quenching by 
some of the B12 analogues, as seen later on. 
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5.2.3 Investigation of the effect of AdoCbl and AdoRbl on the 
btuB riboswitch 
 
In order to further investigate the abilities of AdoCbl binding to and switching off the 
riboswitch, reactions were performed in duplicate using a larger range of 
concentrations (0-60 µM). In vitro protein synthesis reactions were set up as 
described in Chapter 2 (Section 2.3.15) and analysed using western blotting, 
(Figure 5.9). 
 
     0µM 2.5µM 5µM 10µM 20µM 30µM 40µM    60µM 
 





Using densitometry analysis, band intensities from the in vitro reaction samples 
were compared to those from the eGFP standards of known concentration. This 
allowed the relative eGFP concentration in each in vitro reaction sample to be 
calculated. eGFP levels were also analysed by measuring the fluorescence 
Figure 5.9. Western blot analysis showing the effect of AdoCbl on the E. 
coli btuB riboswitch over a 0-60 µM concentration range. Bands represent 
the eGFP present in the in vitro protein synthesis reactions, using the 
Rib70_eGFP_pET14b plasmid in the presence of 0-60 µM AdoCbl. Decreased 
levels of eGFP can be seen as AdoCbl concentration is increased from 0 to 60 
µM in both repeats.  
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intensities emitted by each in vitro reaction sample at 510 nm, after excitation at 488 
nm. Since AdoCbl is coloured at high concentrations, it was checked that it did not 
interfere with eGFP fluorescence. Fluorescence intensities were measured for 
eGFP samples of known concentration, in the presence of various different AdoCbl 
concentrations, in order to prepare eGFP calibration curves at each different 
AdoCbl concentration (Figure 5.10). Very similar readings are seen for fluorescence 
intensity, with or without AdoCbl, suggesting that AdoCbl has no significant effect on 
eGFP fluorescence. Calibration curves were used, corresponding to AdoCbl 
concentration, in order to calculate relative eGFP concentrations in each in vitro 








   
Figure 5.10. Calibration curves for eGFP fluorescence intensity. The 
fluorescence intensity from eGFP samples of 5 different concentrations were each 
measured in the presence of 8 different concentrations of AdoCbl, in order to 
generate calibration curves for each of the different AdoCbl conditions: A) 0 µM B) 
0.25 µM C) 0.5 µM D) 1.0 µM E) 2.0 µM F) 3.0 µM G) 4.0 µM H) 6.0 µM 
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Both densitometry and fluorescence datasets were used to generate graphs 
showing the effect of increasing AdoCbl concentration on the levels of eGFP 






The results confirm the ability of AdoCbl to bind and switch off the riboswitch, as 
there is a decline in eGFP production with the increase of AdoCbl concentration, 
from 2.5 µM to 60 µM.  
 
With these non-linear regression curves (Figure 5.11) an estimated Ki value is 
generated that is determined from the response curve. However, as it is seen that 
AdoCbl does not cause 100% activation (switching off) of the riboswitch, then this Ki 
value does not represent the point at which the switch is 50% off. Since the ligand 
does not cause 100% activation, the maximal activation that it does allow will be 
Figure 5.11. Graphs to show the effect of increasing AdoCbl concentrations 
on riboswitch-controlled eGFP production. Densitometry analysis (left) and 
fluorescence analysis (right) with estimated Ki values of 3.1 +/- 0.3 µM and 0.8 +/- 
0.1 µM, respectively. Note that these Ki values represent 50% of the response, 







used to compare its effectiveness as an activator. This maximal activation will be 
referred to as the AM value. The best activators are those with the highest AM 
values. The fluorescence and densitometry curves suggest AdoCbl activates to a 
maximal level of 82% (AM of 82%) and the concentration where half the maximal 
activation occurs is between 0.8 – 3.1 µM. In this respect, the Ki value (a term that is 
generally defined as the concentration required for half maximal inhibition) 
represents the concentration where 50% of the AM occurs and will henceforth be 
termed as Koff (the switching off constant). Nevertheless, the general trend can still 
be seen, allowing for a comparison between the different B12 variants to see how 
effective these molecules are at activating the riboswitch. 
 
Subsequent to investigating the binding capabilities of AdoCbl, the effect of the 
unnatural AdoCbl analogue, AdoRbl, was explored in the same way. Both 
densitometry and fluorescence analysis were carried out in order to generate 
graphs representing the effect of AdoRbl on riboswitch-controlled eGFP expression. 
Results can be seen in Figures 5.12 and 5.13. 
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Figure 5.12. Western blot analysis showing the effect of AdoRbl on the E. 
coli btuB riboswitch. Bands represent the eGFP present in the in vitro protein 
synthesis reactions, using the Rib70_eGFP_pET14b plasmid in the presence of 
0-60 µM AdoRbl. Decreased levels of eGFP can be seen as AdoRbl 





The results indicate that AdoRbl also binds and switches off the riboswitch, 
displaying similar effects to that of AdoCbl. The estimated Koff values from both 
methods of analysis are very similar, 2.8 µM and 1.9 µM from the fluorescence and 
densitometry, respectively. Both suggest tight binding of AdoRbl to the btuB 
riboswitch. This is not surprising as the structures of AdoCbl and AdoRbl are very 
similar (Widner et al, 2016) . 
 
In order to confirm that the reduction in eGFP production is due to AdoCbl and 
AdoRbl binding the riboswitch, as opposed to them having an effect on the in vitro 
protein synthesis machinery itself, appropriate controls were carried out. This 
involved use of the ‘positive control’ plasmid, eGFP-pET14b, which contains no 
riboswitch and should make eGFP regardless of the presence or absence of B12. 
The plasmid was expressed using the in vitro protein synthesis kit, in the presence 
of no B12, 30 µM AdoCbl, and 30 µM AdoRbl. eGFP levels were compared using 
Figure 5.13. Graphs showing the effect of increasing AdoRbl concentration 
on riboswitch-controlled eGFP production. Densitometry analysis (left) and 
fluorescence analysis (right) with estimated Koff values of 1.9 +/- 0.2 µM and 2.8 
+/- 0.7 µM, respectively. Densitometry analysis and fluorescence analysis 






western blot analysis (Figure 5.14). The results show no visible change in eGFP 
protein band intensity, in the presence of AdoCbl or AdoRbl, suggesting that neither 
have an effect on the in vitro machinery itself and only change eGFP levels when its 
expression is under the control of the btuB riboswitch. 
 
 




Figure 5.14. Western blot analysis of the eGFP present in the AdoCbl and 
AdoRbl control reactions. eGFP-pET14b plasmid tested using the in vitro 
protein synthesis kit, in the presence of no B12, 30 µM AdoRbl and 30 µM 
AdoCbl. AdoCbl and AdoRbl caused no noticeable change to eGFP levels, in the 
absence of a riboswitch, therefore having no visible effect on the in vitro 
machinery. 
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5.2.4 Investigation of the effect of CNCbl, CNCbi and AdoCbi 
on the btuB riboswitch 
 
The investigation of two almost identical analogues, AdoCbl and AdoRbl, provided 
the opportunity to investigate a larger range of corrinoids to learn more about 
molecular recognition by the riboswitch. Therefore, it was decided to look more 
specifically into which regions of AdoCbl are required for binding and changing the 
structure of the riboswitch. Consequently, the next step required looking at a 
corrinoid with a different upper ligand. CNCbl, with a cyano group at the upper 
ligand in place of the 5’-deoxyadenosyl group (found in AdoCbl), was ideal.  
 
Before investigating the effect of CNCbl on the riboswitch, a control experiment was 
performed using eGFP-pET14b to check that CNCbl does not have any effect on 
the in vitro machinery. Western blot analysis showed that CNCbl causes no 
noticeable change to eGFP levels, in the absence of a riboswitch, indicating that 
CNCbl does not affect the in vitro machinery (Figure 5.15).  
 




Figure 5.15. Western blot analysis of the eGFP present in the AdoCbl and 
CNCbl control reactions. The eGFP-pET14b plasmid was tested using the in 
vitro protein synthesis kit, in the presence of no B12, 30 µM AdoCbl and 30 µM 
CNCbl. AdoCbl and CNCbl caused no noticeable change to eGFP levels, in the 
absence of a riboswitch, therefore having no visible effect on the in vitro 
machinery. 
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Using the in vitro protein synthesis kit, eGFP expression within the 
Rib70_eGFP_pET14b plasmid was carried out in the presence of increasing 
concentrations of CNCbl (0 to 1000 µM). Experiments were done in triplicate before 
analysing eGFP production on western blots (Figure 5.16) and by measuring 
fluorescence intensities from each of the reaction samples. Densitometry analysis 
was carried out on the western blots and the results from both methods of analysis 
were compared (Figure 5.17).  
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Prior to fluorescence analysis of the reaction samples, it was important to verify that 
CNCbl has no effect on the change in fluorescence intensity. Therefore, 25 µM 
CNCbl was combined with 1 µM eGFP to see if this had any effect on the 
fluorescence intensity. This was shown to have no visible effect on the fluorescence 
intensity, suggesting that any eGFP fluorescence analyses, in the presence of 
CNCbl, can be reliable. 
Figure 5.16. Western blot analysis showing the effect of CNCbl on the E. 
coli btuB riboswitch. Bands represent the eGFP present in the in vitro protein 
synthesis reactions, using the Rib70_eGFP_pET14b plasmid in the presence of 
0-1000 µM CNCbl. Decreased levels of eGFP can be seen as CNCbl 






Both datasets suggest binding of CNCbl to the btuB riboswitch as well as the ability 
to switch it off, as seen by the gradual decrease in eGFP production with an 
increase in CNCbl concentration. Each method of analysis differs slightly, with less 
visible error coming from the fluorescence analysis. This suggests that, in the 
absence of any fluorescence quenching substrates, fluorescence analysis is the 
more reliable and preferred method of estimating eGFP levels.  
 
The fluorescence curve suggests CNCbl activates to a maximal level of 63% (AM of 
63%) and that the concentration where half the maximal activation occurs is 31.4 
µM. Similarly, the densitometry curve suggests an AM value of 54% and a 
concentration of 77.3 µM required for half maximal activation. Therefore, the results 
indicate that CNCbl is not as strong or productive a ligand as AdoCbl or AdoRbl, 
due to significantly higher Koff values. 
Figure 5.17. Graphs to show the effect of increasing CNCbl concentration 
on riboswitch-controlled eGFP production. Densitometry analysis (left) and 
fluorescence analysis (right) with Koff values of 77.3 +/- 39.2 µM and 31.4 +/- 5.2 
µM respectively. Densitometry analysis and fluorescence analysis suggest AM 







A key question to address here is why do ligands such as CNCbl not cause a 
greater activation of the riboswitch? Why, in this case, is there still a significant 
amount of protein translation taking place even at very high concentrations of 
CNCbl? This is likely due to the way in which the molecule binds to the riboswitch, 
binding largely in a non-productive manner that does not allow complete activation 
of the switch. 
 
Next, the effects of CNCbi and AdoCbi on the riboswitch, both lacking the 
cobalamin lower loop, were studied. First, control experiments were carried out in 
order to confirm that they do not have an effect on the in vitro protein synthesis 
machinery itself. Again, eGFP-pET14b plasmid was expressed using the in vitro 
protein synthesis kit, in the presence of 0 µM B12, 30 µM AdoCbi and 30 µM CNCbi. 
eGFP production was analysed using western blots (Figure 5.18). The results show 
no visible difference in eGFP protein band intensity in the presence or absence of 
either Cbi (Figure 5.18).  
 
 




Figure 5.18. Western blot analysis of the eGFP present in the AdoCbi and 
CNCbi control reactions. The eGFP-pET14b plasmid was tested using the in 
vitro protein synthesis kit, in the presence of no B12, 30 µM AdoCbi and 30 µM 
CNCbi. AdoCbi and CNCbi caused no noticeable change to eGFP levels, in the 
absence of a riboswitch, therefore having no visible effect on the in vitro 
machinery. 
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When investigating the effects of AdoCbi and CNCbi on the riboswitch, fluorescence 
analysis could not be used. This was due to quenching of eGFP fluorescence by 
AdoCbi and CNCbi. Tests were carried out in which a 25 µM sample of each Cbi 
was combined with 1 µM and 4 µM eGFP to see the effect on fluorescence 
intensity. Results showed a significantly diminished eGFP fluorescence reading in 
the presence of each Cbi. Therefore, eGFP production within each in vitro reaction 
sample was analysed using densitometry of bands on western blots (Figures 5.19 
and 5.20).  
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Figure 5.19. Western blot analysis showing the effect of AdoCbi on the E. 
coli btuB riboswitch. Bands represent the eGFP present in the in vitro protein 
synthesis reactions, using the Rib70_eGFP_pET14b plasmid in the presence of 
0-40 µM AdoCbi. Decreased levels of eGFP can be seen as AdoCbi 
concentration is increased in all three repeats. 
Figure 5.20. Western blot analysis showing the effect of CNCbi on the E. 
coli btuB riboswitch. Bands represent the eGFP present in the in vitro protein 
synthesis reactions, using the Rib70_eGFP_pET14b plasmid in the presence of 
0-60 µM CNCbi. Decreased levels of eGFP can be seen as CNCbi concentration 
is increased in all three repeats. 
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Densitometry analysis was carried out in order to generate curves representing the 






The fluorescence analysis graphs show that both AdoCbi and CNCbi are capable of 
binding to the btuB riboswitch and causing a change in its structure to hinder gene 
expression. However, AdoCbi appears to have greater binding capabilities than 
CNCbi, since it has an AM value of 55% compared to that of CNCbi (48%). It seems 
that while AdoCbl and AdoRbl are very good at switching off the riboswitch, these 
other variants are not so good. The most these other variants appear to be able to 
do is bind and switch off expression to get approximately 50% of production. As with 
CNCbl, it could be that AdoCbi and CNCbi are binding to the riboswitch but not 
binding in a productive way that is able to switch off the riboswitch.   
Figure 5.21. Graphs to show the effect of increasing AdoCbi and CNCbi 
concentrations on riboswitch-controlled eGFP production. eGFP production 
was analysed using densitometry analysis of eGFP bands on western blots. Koff 
values are 8.6 +/- 4.7 µM and 14.2 +/- 9.6 µM for AdoCbi and CNCbi, 







5.2.5 Investigation of the effect of further unnatural 
cobalamin variants on the btuB riboswitch 
 
Other unnatural cobalamin variants (produced by the research group of Professor 
Bernhard Kräutler) which differ in their upper ligand or completely lack the upper 
ligand (due to a change to the central metal ion), were tested for their effect on the 
riboswitch. This was done in order to see whether they could be potential 
antivitamins that display similar activity to AdoRbl. These variants include 
ethylphenylcobalamin (EtPhCbl), difluorophenylethinylcobalamin (F2PhEtyCbl), with 
ethylphenyl and difluorophenylethinyl upper ligands, respectively, and zincobalamin 
(Znbl) and nibalamin (Nibl), with zinc and nickel as their central metal ions, 
respectively. Beforehand, it had been seen that a change from cobalt to rhodium 
had very little effect, if any, on riboswitch recognition and binding. This time, 
however, the two new metal ions are unable to coordinate an upper ligand as done 
so by cobalt and rhodium. 
 
Experiments were carried out in duplicate using the PURExpress in vitro protein 
synthesis kit, followed by eGFP detection on western blots and analysis using 
densitometry. Due to the quenching of fluorescence by all four unnatural variants, 
fluorescence analysis could not be used as a method of eGFP quantification.  
 
The bands from the western blots indicate that increasing concentrations of EtPhCbl 
have no effect on eGFP levels (Figure 5.22), and therefore on the riboswitch. This 




0 2.5           5 10 20 30 40 60 100 1000 
 
 









Next, the effect of F2PhEtyCbl on the riboswitch was investigated. The western blots 
showed no clear indication of what effect F2PhEtyCbl was having on eGFP levels 





























Figure 5.22. Western blot analysis showing the effect of EtPhCbl on the E. 
coli btuB riboswitch. Bands represent the eGFP present in the in vitro protein 
synthesis reactions, using the Rib70_eGFP_pET14b plasmid in the presence of 
0-1000 µM EtPhCbl. EtPhCbl has no effect on eGFP levels in both repeats.  
Figure 5.23. Graphs to show the effect of increasing EtPhCbl concentrations 
on riboswitch-controlled eGFP production. eGFP production was analysed 
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F2PhEtyCbl (Ki = 340.2 µM) 
Figure 5.24. Western blot analysis showing the effect of F2PhEtyCbl on the E. 
coli btuB riboswitch. Bands represent the eGFP present in the in vitro protein 
synthesis reactions, using the Rib70_eGFP_pET14b plasmid in the presence of 0 - 
60 µM F2PhEtyCbl as well as at two higher concentrations of 100 µM and 1000 µM.  
Figure 5.25. Graphs to show the effect of increasing F2PhEtyCbl 
concentrations on riboswitch-controlled eGFP production. eGFP production 
was analysed using densitometry of eGFP bands on western blots. No effect was 










Results from the densitometry analysis suggest that F2PhEtyCbl could have an 
effect on eGFP expression at higher concentrations, such as 1 mM. However, a 
broader range of concentrations would need to be tested within the 100 µM to 1 mM 
range in order to verify this. Additionally, to confirm F2PhEtyCbl was not having an 
effect on the in vitro protein synthesis machinery, control experiments were carried 
out (Figure 5.26). These confirmed that F2PhEtyCbl did not have an effect on the in 









Finally, the effects of Znbl and Nibl were investigated. Results from the western 
blots (Figures 5.27 and 5.28) and densitometry analyses (Figure 5.29) showed that 
the variants have no effect on the riboswitch. 
  
Figure 5.26. Western blot analysis of the eGFP present in the F2PhEtyCbl 
control reactions. The eGFP-pET14b plasmid was tested using the in vitro 
protein synthesis kit, in the presence of no B12 and 30 µM F2PhEtyCbl. 
F2PhEtyCbl caused no noticeable change to eGFP levels in the absence of a 
riboswitch, therefore having no visible effect on the in vitro machinery.  
 173 
0µM 10µM 20µM 40µM 60µM 100µM 
 
0µM 10µM 20µM 40µM 60µM 100µM 
 







0µM 10µM 20µM 40µM 60µM 100µM 
 
0µM 10µM 20µM 40µM 60µM 100µM 
 







Figure 5.27. Western blot analysis showing the effect of Znbl on the E. coli 
btuB riboswitch. Bands represent the eGFP present in the in vitro protein 
synthesis reactions, using the Rib70_eGFP_pET14b plasmid in the presence of 
0-100 µM Znbl. Znbl has no effect on eGFP levels in all three repeats. 
Figure 5.28. Western blot analysis showing the effect of Nibl on the E. coli 
btuB riboswitch. Bands represent the eGFP present in the in vitro protein 
synthesis reactions, using the Rib70_eGFP_pET14b plasmid in the presence of 






In both datasets (Figure 5.29) there appears to be no direct effect of increasing 
ligand concentration on the eGFP concentration detected at the end of each 
reaction. Results show that neither of the analogues have an effect on the 
riboswitch. This is most likely due to the fact that both of these B12 variants lack an 
upper ligand. Unlike rhodium, which has a very similar coordination chemistry to 
cobalt, the zinc and nickel ions in these two compounds are unable to coordinate an 
upper ligand. Therefore, the most likely explanation for their inability to induce 
riboswitch recognition and binding is their lack of the crucial upper ligand group.  
Figure 5.29. Graphs to show the effect of increasing Znbl and Nibl 
concentrations on riboswitch-controlled eGFP production. eGFP production 
was analysed using densitometry analysis of eGFP bands on western blots. No 










5.2.6 Investigating the potential of reversing the riboswitch 
control over eGFP reporter gene expression 
 
Following on from the work done on the E. coli btuB riboswitch, where a system was 
developed that allows a decline in eGFP production to be seen with the addition of 
known concentrations of B12, a new system was developed here that involves 
reversing the current workings similar to that done by Cai et al. In this system (the 
reverse riboswitch system), the E. coli btuB riboswitch (including the first 70 codons 
of btuB) is placed directly in front of the tetR gene such that B12 is able to switch off 
tetR expression and control production of TetR. The riboswitch-tetR fragment is 
under the control of the PJ23110 promoter (medium strength constitutive promoter 
designed by John Anderson at the iGem group in Berkeley, 2006). Meanwhile, 
eGFP is placed under the control of the PTetA promoter which is controlled by TetR 
due to its ability to switch off any expression reliant on the PTetA promoter. Thus, B12 








The system was designed with the addition of strategically placed restriction sites 
around each component (PJ23110, btuB riboswitch, tetR gene, PTetA promoter, eGFP 
gene), such that the components can be modified at any point. The sequence was 
then sent to Eurofins so that the 2235 bp DNA fragment (NK DNA) could be 
synthesised. The synthesised DNA was received in the form of a plasmid, 
NK_DNA_pEX-A258, containing an ampicillin resistance gene for selection 
purposes.  
 
In order to test the functionality of the plasmid, transformation of JM109 was carried 
out with NK_DNA_pEX-A258 and used for the preparation of overnight starter 
cultures, with and without B12, to see whether this caused a difference in eGFP 
production. From the presence of green-coloured bacterial pellets, it was seen that 
all four cultures (no B12, 30 µM AdoCbl, 30 µM CNCbl and 30 µM OHCbl) were 
Figure 5.30. Diagrammatic representation of the reverse riboswitch system 
in the presence and absence of B12 (red circle). In the absence of B12 (above), 
the riboswitch is switched on and tetR is expressed. The TetR protein is then able 
to negatively control eGFP expression by binding to the PTetA promoter. This 
should lead to a lack of eGFP production. In the presence of B12 (below), TetR is 
not produced and therefore eGFP production is unhindered. Image Source: Dr. 
Evelyne Deery. 
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producing eGFP. The test was repeated using minimal medium with the addition of 
1 mM thiamine, instead of LB, in order to prevent contamination of B12 in any 
samples (particularly the sample that should have no B12). However, the results 
were the same and the use of minimal medium instead of LB made no difference. 
This suggests that, even in the absence of B12, the levels of TetR are too low, for 
which reason TetR is unable to switch off eGFP production. In order to confirm this, 
TetR production would need to be looked into further in each of the various 
conditions.  
 
Before investigating TetR production, a new plasmid (called NK_DNA2_pEX-A258) 
was constructed in which the promoter upstream of the riboswitch was changed 
from PJ23110 to PTetR (also a constitutive promoter). This allows TetR production 
levels, under the control of two different promoters, to be compared to see which is 
preferred in this particular application, and to see if there is a difference. To change 
the promoter, the NK_DNA_pEX-A258 plasmid was digested using the StuI 










New assays were set up in minimal medium using transformants carrying one of 
each of the two plasmid variants. Each transformant was grown up in two different 
conditions, no B12 and 30 µM AdoCbl, with each reaction carried out in duplicate. 
Following overnight growth, samples were prepared as described in Chapter 2 
(Section 2.3.16) and eGFP levels analysed using SDS-PAGE (Figure 5.32). 
  
Figure 5.31. Diagram to compare the reverse riboswitch system in 
NK_DNA_pEX-A258 (above) and in NK_DNA2_pEX-A258 (below). 
NK_DNA_pEX-A258 has tetR under the control of PJ23110, whereas 
NK_DNA2_pEX-A258 has tetR under the control of PTetR.  
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The SDS-PAGE analysis (Figure 5.32) suggests that eGFP (26.8 kDa) is present in 
all the samples. In order to confirm that these bands represent eGFP, a western blot 
was carried out using antibodies against eGFP (Figure 5.33).  
  
Figure 5.32. SDS-PAGE analysis comparing eGFP levels within JM109-
NK_DNA_pEX-A258 and JM109-NK_DNA2_pEX-A258 in the presence and 
absence of B12. Lanes 1-4; JM109-NK_DNA_pEX-A258 with the PJ23110 promoter 
controlling tetR, lanes 5-8; JM109-NK_DNA2_pEX-A258 with the PTetR promoter 
controlling tetR. Lanes 3, 4, 7 and 8 contain samples from cultures prepared with 
the addition of 30 µM AdoCbl. eGFP (26.8 kDa) appears to be present in all 
samples with no visible difference in results between the two bacterial strains. 
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The western blot confirms the presence of eGFP in each of the samples. However, 
the addition of B12 does not appear to increase the levels of eGFP as expected in 
the reverse riboswitch system. The presence of B12 is ideally expected to switch off 
tetR expression and in turn lead to maximum levels of eGFP production (Figure 
5.30). It may be that, even in the absence of B12, TetR levels are too low to have 
any effect on the PTetA promoter (controlling eGFP expression). Alternatively, it may 
be that the hybrid form of TetR (TetR fused with the first 70 amino acids of BtuB) is 
unable to dimerise like regular TetR (Orth et al, 2000). This hybrid form of TetR may 
not then be able to bind the PTetA promoter. Additionally, in the case that TetR-BtuB 
does dimerise, the 70 amino acids of BtuB at the N-terminus of TetR could be 
interfering with TetR binding to DNA, since it is the N-terminus of TetR that is 
involved in DNA binding (Orth et al, 2000). In order to better understand what is 
happening, TetR levels in each condition would need to be analysed closely and 
Figure 5.33. Western blot analysis comparing eGFP levels within JM109-
NK_DNA_pEX-A258 and JM109-NK_DNA2_pEX-A258 in the presence and 
absence of B12. Lanes 1-4; JM109-NK_DNA_pEX-A258 with the PJ23110 promoter 
controlling tetR, lanes 5-8; JM109-NK_DNA2_pEX-A258 with the PTetR promoter 
controlling tetR. Lanes 3, 4, 7 and 8 contain samples from cultures prepared with 
the addition of 30 µM AdoCbl. eGFP (26.8 kDa) appears to be present in all 
samples with no visible difference in results between the two bacterial strains. 
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compared to eGFP levels. Future work could also involve moving on to the use of 




Numerous studies on the E. coli btuB riboswitch have determined that there is a 
requirement for the 5’-deoxyadenosyl group, at the upper ligand position of B12, in 
order to bind the B12-binding pocket of the riboswitch and allow structural 
modulation of the RNA. Many of these studies have used in-line probing to show 
that AdoCbl is the preferred ligand for the btuB riboswitch (Nahvi et al, 2002; Nou 
and Kadner, 2000).  
 
In this thesis, the effectiveness of various different B12 analogues, both natural and 
unnatural, in binding to and switching off the E. coli btuB riboswitch has been 
investigated using in vitro assays. This involved the use of an in vitro 
transcription/translation kit, since it was thought that this might allow more accurate 
determination of the ability of the riboswitch to respond to B12 concentrations and 
different B12 types. eGFP reporter concentrations were measured using both 
fluorescence analysis and densitometry of western blot bands. However, 
fluorescence analysis could not be done for all the experiments since certain B12 
variants caused quenching of eGFP fluorescence.  
 
Fluorescence analysis showed decreasing levels of eGFP production in the 
presence of increasing concentrations of AdoCbl, AdoRbl, CNCbl, AdoCbi and 
CNCbi. Densitometry analysis provided very similar results, but with slightly larger 
scope for error. Hence it can be assumed that each of these B12 variants are able to 
bind to the btuB riboswitch and cause a change in its structure, such that the RBS 




As seen from the response curves, the ligands do not appear to have the ability to 
cause 100% activation (switching off) of the riboswitch. Therefore, AM (maximal 
activation) and Koff values (the concentration where 50% of the AM occurs) were 
used to compare how effective the different B12 variants are at activating the 
riboswitch. A summary of these values can be found in Table 5.1. The most 






A comparison between different B12 variants on their effect on the E. coli 





Koff (µM) Standard Error 
for Koff value 
AM (%) 
AdoCbl Fluorescence 0.8 +/- 0.1 82 
AdoCbl Densitometry 3.1 +/- 0.3 82 
AdoRbl Fluorescence 2.8 +/- 0.7 73 
AdoRbl Densitometry 1.9 +/- 0.2 78 
CNCbl Fluorescence 31.4 +/- 5.2 63 
CNCbl Densitometry 77.3 +/- 39.2 54 
AdoCbi Densitometry 8.6 +/- 4.7 55 
CNCbi Densitometry 14.2 +/- 9.6 48 
 
 
The AM and Koff values for each riboswitch binding ligand, as summarised in Table 
5.1, show the most effective at binding and switching off the riboswitch to be 
AdoCbl, with an AM value of 82%, followed by its analogue AdoRbl, with an AM value 
of 73-78%. This means that both AdoCbl and AdoRbl have the ability to cause 
Table 5.1. Table to compare Koff and AM values for each ligand. Koff and AM 
values were obtained from fluorescence and densitometry analysis for AdoCbl, 




around 80% activation of the riboswitch, thereby causing a reduction in protein 
synthesis by 80%.  
This supports the well-known theory that AdoCbl is the preferred ligand for the E. 
coli btuB riboswitch. Previous studies, using primer extension-inhibition assays, 
have even estimated a Ki of AdoCbl at 0.3 µM (Nou and Kadner, 2000). Following 
this, further studies using in-line probing yielded apparent KD values of 0.3 µM for 
AdoCbl binding to the btuB riboswitch (Nahvi et al, 2002). Although Ki values in this 
study were not representative of half the concentration required for full inhibition 
(since full switching off could not be observed), Koff values were used instead to 
represent half the maximal activation of the riboswitch. These allowed an effective 
comparison between B12 variants and meant that the activating potential of 
analogues or antivitamins could be compared. For example, the antivitamin AdoRbl 
had a Koff value of between 1.9 and 2.8 µM which was very close to that of the 
preferred ligand AdoCbl, with a Koff value of 0.8 to 3.1 µM. This suggests that 
AdoRbl has high potential to be used an AdoCbl inhibitor as opposed to the 
remaining antivitamins, which were seen to have no effect on the riboswitch. 
 
The natural cobalt ion has an important role in coordination of the upper and lower 
ligand. In AdoRbl, cobalt is replaced with rhodium. Since cobalt and rhodium share 
a similar coordination chemistry, rhodium is able to hold the same groups as cobalt 
to form AdoRbl (Widner et al, 2016). The work presented in this thesis has shown 
that the change from cobalt to rhodium has little effect on riboswitch recognition and 
binding. However, when testing two other analogues with unnatural central metal 
ions, the difference in results was dramatic. Nibl and Znbl were both seen to have 
no effect on the riboswitch despite the use of larger concentrations. The reason for 
this is most likely to be the differing coordination chemistry to cobalt, for which 
reason nickel and zinc are only able to form five bonds and cannot coordinate an 
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upper ligand. This again highlights the importance of the upper ligand, as opposed 
to the central metal ion itself, in riboswitch recognition and binding. 
 
In summary, the work described in this report confirms the requirement for the 5’-
deoxyadenosyl group in the control of the E. coli btuB riboswitch. The results also 
confirm the ability of the unnatural analogue, AdoRbl, to mimic AdoCbl and cause a 
similar effect on the riboswitch, suggesting that it has the potential to control BtuB 
protein production and therefore cobalamin uptake. In terms of mimicking the 
functions of AdoCbl, AdoRbl would be unable to do so due to its lack of the crucial 
hydrolysable C-Co bond that allows AdoCbl to function as a coenzyme. This means 
that AdoRbl would be recognised by cells as AdoCbl, but B12-dependent enzymes 
would remain inactive, thus giving AdoRbl the potential to put cells in a B12-starved 
state and inhibit further growth. Thus, AdoRbl can be said to have antivitamin 
potential (binding the same sites as B12, but without carrying out the same function). 
Through further research, such antivitamins could potentially be used for the 
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6.1 General discussion 
The fascinating world of B12 research began in the early 1920’s, through the work of 
three researchers, Whipple, Minot and Murphy, who demonstrated that they were 
able to cure pernicious anaemia with the addition of whole liver in the diet  (Whipple 
et al, 1920). This then led to the discovery of the “anti-pernicious anaemia factor”, 
vitamin B12, whose three-dimensional structure was later deduced by Dorothy 
Hodgkin in 1955 (Hodgkin et al, 1955). Following on from this, the work of several 
different research groups identified multiple B12-dependent enzymes, in all 
kingdoms of life. Such studies have helped generate a greater understanding of the 
role of the molecule in metabolism and the consequences of its absence.  
Subsequently, years of research has built up an extensive idea of how this structure 
is synthesised from uroporphyrinogen III, through a series of around 30 complex 
enzyme-mediated steps, in bacteria, to form nature’s most complex vitamin (Warren 
et al, 2002). Not only has the biological synthesis been elucidated, but the total 
chemical synthesis of B12 has also been achieved, an outstanding achievement that 
was orchestrated by Woodward and Eschenmoser. The chemical synthesis 
involved the dedicated work of over 100 scientists, during a period of 11 years 
between the 1960s and 1970s. Utilising the knowledge attained from both the 
biosynthesis and chemical synthesis of B12 has allowed current scientists to create a 
range of different B12 variants, both natural and unnatural. 
The work carried out here investigates the possibility of engineering the production 
of B12 analogues, through the construction of an empty, metal-free B12 shell, and 
exploring what effect such compounds might have on cellular control elements, 
such as riboswitches. In 1965, metal-free corrinoids were first discovered and 
isolated from the photosynthetic bacterium, A. vinosum (Toohey, 1965), and hence, 
enzymes from this bacterium were used in this project to construct an empty, metal-
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free B12 shell to be used as the starting point for creating new B12 analogues. 
Unfortunately, this approach did not work, most likely due to the inactivity of one or 
more of the A. vinosum enzymes. Therefore, analogues provided by the Krautler 
group were used in investigating the effect of such compounds on a B12-dependent 
riboswitch. 
In order to study this, a method was designed and developed that utilises an in vitro 
transcription/translation system to determine the effect of both natural and unnatural 
B12 analogues on the well-characterised B12-dependent riboswitch, known as the 
btuB riboswitch. This method allowed a quick and easy way of testing the ability of 
B12 variants to directly bind to and deactivate the btuB riboswitch, without relying on 
indirect cellular effects. eGFP production was monitored in the presence of AdoCbl, 
AdoRbl, CNCbl, AdoCbi, CNCbi, Nibl, Znbl, EtPhCbl and F2PhEtyCbl. The results 
showed that AdoCbl and AdoRbl had the greatest effect on the riboswitch, with 
AdoRbl closely mimicking the levels of inhibition caused by AdoCbl. CNCbl, AdoCbi 
and CNCbi were seen to have much lesser effects and required higher 
concentrations to cause similar effects to that of AdoCbl or AdoRbl. The remaining 
four unnatural B12 variants were seen to have little effect, if any, on the E. coli btuB 
riboswitch. 
The work described in this thesis confirms that an adenosyl group in place of the 
upper ligand is crucial to control of the E. coli btuB riboswitch. The demonstration 
that AdoRbl is able to mimic AdoCbl and bind to the riboswitch highlights the 
potential for such analogues, with the required components for recognition, to 
interfere with and inhibit cellular processes. Since AdoRbl binds to the riboswitch in 
the same way as AdoCbl, it is also likely to bind any B12-dependent enzymes that 
recognise AdoCbl. In terms of mimicking the functions of AdoCbl as a coenzyme, 
AdoRbl would be unable to do so due to the lack of the crucial hydrolysable C-Co 
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bond that allows AdoCbl to participate in chemical reactions. This has been shown 
in recent work by Widner et al where the provision of AdoRbl to B12-dependent cells 
caused thinner, more spread out growth, suggesting that AdoRbl is binding the btuB 
riboswitch and causing reduced levels of btuB gene expression and therefore 
reduced B12 uptake (Widner et al, 2016). However, since the AdoRbl was unable to 
work with B12-dependent enzymes, growth was less dense compared to when using 
CNCbl (Widner et al, 2016). The work presented in this thesis has confirmed that 
AdoRbl does indeed bind to the btuB riboswitch to reduce the levels of btuB gene 
expression. Together, this all demonstrates that analogues such as AdoRbl have 
the potential to disrupt biological systems, by inactivating B12-dependent enzymes 
and putting cells in a B12-starved state, opening up a whole new area of research 
into the use of B12 analogues as antibacterial agents. 
 
Researchers have already begun exploiting the fundamental knowledge acquired 
on riboswitches by designing riboswitches with medicinal and biotechnological 
applications. One such example involves the recent synthesis of functional 
riboswitches that are able to detect explosives, due to the design of an aptamer 
domain that is able to bind a component known as 2,4-dinitrotoluene (2,4-DNT), 
commonly found in explosives (Borujeni et al, 2015).  
 
In other applications, riboswitches are being utilised as powerful RNA imaging tools 
to elucidate mechanisms such as those underlying the dynamics of the mRNA and 
ncRNA life cycle. Here, an RNA tag has been developed containing a B12-riboswitch 
as well as Cbl-fluorophore probes, in which the fluorescence of a synthetic 
fluorophore is quenched by Cbl until Cbl binds to the B12-riboswitch, found in the 




In addition to this, riboswitches controlling key metabolic systems in pathogenic 
organisms can be exploited through the use of metabolite/ligand analogues for the 
development of antibacterial compounds (Blount and Breaker, 2006). These 
advances suggest that the continued discovery and analysis of riboswitches will 
allow progress in creating more useful molecular tools as well as help in the 
identification of drug targets. The work presented in this thesis has shown the ability 
of AdoRbl to work as an effective B12 inhibitor in the case of one particular B12-
dependent riboswitch, the btuB riboswitch. However, by investigating a whole other 
range of riboswitches, it could be that other riboswitches require different 
components for recognition, instead of the upper ligand, as in the case of the btuB 
riboswitch. It may be that different riboswitches prefer analogues such as Znbl or 
Nibl, without upper ligands, over AdoRbl. Thus, the research carried out in this 
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